WO2015147559A1 - Composition for promoting growth comprising chaenomeles sinesis as active ingredient - Google Patents
Composition for promoting growth comprising chaenomeles sinesis as active ingredient Download PDFInfo
- Publication number
- WO2015147559A1 WO2015147559A1 PCT/KR2015/002949 KR2015002949W WO2015147559A1 WO 2015147559 A1 WO2015147559 A1 WO 2015147559A1 KR 2015002949 W KR2015002949 W KR 2015002949W WO 2015147559 A1 WO2015147559 A1 WO 2015147559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth
- quince
- tree
- composition
- present
- Prior art date
Links
- 230000012010 growth Effects 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 230000001737 promoting effect Effects 0.000 title claims abstract description 36
- 239000004480 active ingredient Substances 0.000 title claims abstract description 29
- 241001507936 Chaenomeles Species 0.000 title abstract 4
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 235000017788 Cydonia oblonga Nutrition 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 11
- 229940069774 quince extract Drugs 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 230000008468 bone growth Effects 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 4
- 239000007952 growth promoter Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 22
- 239000000122 growth hormone Substances 0.000 abstract description 20
- 102000018997 Growth Hormone Human genes 0.000 abstract description 19
- 108010051696 Growth Hormone Proteins 0.000 abstract description 19
- 230000000366 juvenile effect Effects 0.000 abstract 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 64
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 64
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 60
- 241000700159 Rattus Species 0.000 description 16
- 210000004349 growth plate Anatomy 0.000 description 16
- 210000002303 tibia Anatomy 0.000 description 16
- 108090000573 Osteocalcin Proteins 0.000 description 13
- 102000004067 Osteocalcin Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 230000001969 hypertrophic effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000010603 microCT Methods 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012756 BrdU staining Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229920002472 Starch Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000009578 growth hormone therapy Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000007602 hot air drying Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000001621 ilium bone Anatomy 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229940092385 radish extract Drugs 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OEUQYZJFHCQSRB-UHFFFAOYSA-N ClC(Cl)Cl.ClC(Cl)Cl.C1=CC=CC=C1 Chemical compound ClC(Cl)Cl.ClC(Cl)Cl.C1=CC=CC=C1 OEUQYZJFHCQSRB-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000236931 Cydonia oblonga Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100031475 Osteocalcin Human genes 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- -1 vitamin lipids Chemical class 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Definitions
- the present invention relates to a growth promoting effect of Chinese quince, and more particularly to a pharmaceutical composition for promoting growth, a food composition and a composition for animal feed comprising the Chinese quince as an active ingredient.
- Bone (bone) tissue is a specially differentiated connective tissue, which is composed of several types of cells such as mesenchymal cells, chondrocytes, osteoblast osteoclasts, and bone marrow cells. There is a balance between the amount of bone resorption by osteoclasts and the amount of bone formation by osteoblasts. In the growth period, bone growth is greater than the amount of bone resorption by osteoblasts. Will be done.
- the growth piate is a group of horizontally shaped cartilaginous cells located at both ends of the long bone, located between the metaphys is and the epiphysi s. After the growth of chondrocytes, growth of hypertrophy, secretion of extracellular epilepsy, invasion of blood vessels and bone precursor cells and oss ifi cat ion During the process of endochondral oss ifi cat ion where the cartilage is turned into bone, new bone is continuously formed at the end of the bone trunk of the growth plate, thereby lengthening the long bone.
- Growth plate is castle It is regulated by hormones such as intestinal hormone, insul in- ike growth factor (IGF), thyroid hormone, sex hormone, and glucocorticoids and various cytokines, which eventually become ossified and fuse with surrounding bones ( Shin, Ho-Ho, 2006, Hormone Growth Edition, Korean Society of Pediatric Endocrinology, vol 11, 117-122.
- hormones such as intestinal hormone, insul in- ike growth factor (IGF), thyroid hormone, sex hormone, and glucocorticoids and various cytokines, which eventually become ossified and fuse with surrounding bones ( Shin, Ho-Ho, 2006, Hormone Growth Edition, Korean Society of Pediatric Endocrinology, vol 11, 117-122.
- a growth hormone preparation administration method As a method for promoting growth, a growth hormone preparation administration method, an irizanov operation method, and a dietary supplement taking method have been used.
- growth hormone therapy which has been used in the past for pathologically sluggish growth, has been applied to growing children and adolescents with normal kidneys as their interest in height growth has recently increased.
- the method of administration of the growth hormone preparation shows an excellent effect in the case of the lack of growth hormone, but the majority of people with normal hormone secretion have various side effects such as positive terminal hypertrophic growth hormone antibody, systemic allergic reaction, hypothyroidism, etc. There is a problem that can be caused.
- problems such as excessive duration and cost of growth hormone therapy, cancer, and disturbance of other growth factors have been found.
- ilizanov surgery is an operation that is performed after cutting the bone of the leg, and it is difficult to use it for the general public in terms of pain and cost of patients, and growth supplements are mostly scientifically untested. . ⁇ 10> Therefore, the efficacy of promoting growth is scientifically verified and the development of safe food materials is required.
- the present inventors while studying to develop a food material having an activity that effectively promotes growth without side effects, confirmed the effect of growth plate promotion and iliac bone length increase in experimental animals administered quince and completed the present invention.
- an object of the present invention is to provide a pharmaceutical composition for promoting growth comprising a Chinese quince as an active ingredient.
- Another object of the present invention is to provide a growth promoting food composition comprising a Chinese quince as an active ingredient.
- Another object of the present invention to provide a composition for promoting animal feed comprising a Chinese quince as an active ingredient.
- Another object of the present invention is to provide the use of Chinese quince for the production of growth promoters.
- Another object of the present invention is to provide a use of Chinese quince for preparing a food composition for growth promotion.
- Another object of the present invention is to provide a use of Chinese quince for the production of animal feed for growth promotion.
- Another object of the present invention is to provide a method for promoting growth, comprising administering an effective amount of a Chinese quince to an individual in need of growth.
- the present invention provides a pharmaceutical composition for growth promotion comprising a Chinese quince as an active ingredient.
- the present invention provides a food composition for growth promotion comprising a Chinese quince as an active ingredient.
- the present invention provides a composition for promoting animal feed comprising a Chinese quince as an active ingredient.
- the present invention provides the use of a Chinese quince tree for the production of growth promoters.
- the present invention provides the use of the Chinese quince for producing a food composition for promoting growth.
- the present invention provides a feed for promoting animal growth
- the use of Chinese quince for manufacturing Provided is the use of Chinese quince for manufacturing.
- the present invention provides a method for promoting growth, comprising administering an effective amount of a Chinese quince to an object in need of growth. .
- the present invention will be described in detail.
- the present invention provides a growth promoting composition comprising a Chinese quince as an active ingredient.
- the quince tree (qui nce t ree, Chaenomeles sinensis ⁇ ) is a deciduous tree of the dicotyledonous rosacea rosaceae, which has several aliases such as Cydonia sinensis, Pseudocydonia sinensis, Cydonia sinensis, and Cydonia oblonga.
- the Chinese quince tree of the present invention is not limited to any part constituting the Chinese quince, but preferably may be one or more selected from the group consisting of fruit leaves, flowers, stems and roots of the Chinese quince, more preferably It can be a quince fruit.
- the fruit of the Chinese quince tree is mainly called the herbal name Chaenomelis Fructus, ⁇ ), the tree family is also called quince, quince, tree fruit, incense, and the corresponding neck, hairpin , iron shell , etc., specification of the present invention In the above, the above terms may be commonly used.
- the Chinese quince tree of the present invention can be processed or used as it is or in a form that can be administered to an animal, but is not limited thereto, and may be, for example, a powder, a suspension extract, and the like.
- Organic solvents include alcohols, acetone, Ether, benzene, chloroform, ethyl acetate, methylene chloride, nucleic acid, cyclohexane, diethyl ether and petroleum ether It may be selected from the group consisting of (petroleum ether). Preferably it can be extracted using water or alcohol having 1 to 6 carbon atoms.
- the Chinese quince extract may include a pretreatment process to increase the extraction efficiency, for example, may be used by grinding the Chinese quince with a grinder.
- Extraction temperature of the extract of the present invention is not particularly limited, and may be, for example, 0 ° C to 15 C C, preferably 80 ° C to 120 ° C.
- Extraction time of the extract of the present invention is not particularly limited depending on the degree of extraction silver, for example may be 10 minutes to 10 days, preferably 30 minutes to 24 hours, more preferably from 1 hour to 6 It can be time.
- Extract of the present invention can be extracted by known natural product extraction method. For example, it can be extracted by ⁇ acupuncture extraction, hot water extraction, ultrasonic extraction ⁇ reflux ⁇ angle extraction, heating extraction ⁇ preferably can be extracted by hot water extraction or reflux ⁇ angle extraction method, once to 10 times, preferably The extraction can be repeated two to seven times.
- a filtration process, a concentration and purification process, a drying process, a freezing process, and a powdering process may be arbitrarily added for ease of treatment, storage, and the like during the preparation of the Chinese quince extract of the present invention.
- the filtration process may be based on a known filtration method, but is not limited thereto. For example, filtration, centrifugation, and separatory funnel using a filtration network or a micro filter may be used.
- the concentration process may be performed by a known concentration method, but is not limited thereto.
- the concentration process may be concentrated using precipitation concentration, evaporation concentration, reduced pressure concentration, oriental filtration, reverse osmosis, and centrifugation.
- the concentration is preferably 3 to 50% by weight, more preferably 10 to 20% by weight, and most preferably 14 to 16% by weight, based on the amount of solids. Can be enriched with have.
- the solids means an active ingredient remaining when all the solvents of the extract are evaporated, and the present invention includes both soluble solids and insoluble solids.
- the drying process may be by a known drying method, but is not limited thereto, and may be, for example, freeze drying, spray drying, or hot air drying.
- the powdering process may be by a known powdering method, but is not limited thereto, for example, it may be powdered by a process such as dextrin inclusion.
- the extract of the present invention may be powdered by the method of hot air drying by adding crystalline salose as an inert excipient.
- the addition rate of the crystalline cell may be added in a ratio of 1: 1 to 10, based on the solid content weight, preferably 1: 0.1 to 5, and most preferably 1: 0.5 to 2 Can be.
- the most preferred embodiment of the present invention is an extract of the neck family.
- the neck and extracts are not limited thereto, and preferably, may be prepared by a hot water extraction method using water as a solvent.
- the ratio of neck and water during the extraction of hot water is not particularly limited, but water may be added to the neck 3 times to 20 times (increase). Preferably, water can be added 15-19 times (by weight) to the tree to increase the extraction effect.
- the Chinese quince extract of the present invention was put into 10L of water and 600g crushed to the size of 20-40 mesh and extracted with hot water twice at 10C C for 2 hours.
- the hot water extract was left to cool to cool, filtered and concentrated until the solid content was 15% by weight in the pre-softening phase, and the crystalline cells were mixed and dried in the concentrate to prepare neck and extract powder.
- the growth of the present invention refers to an increase in the size and function of each organ of the body, and preferably to increase the size, thickness, density, length, function increase and growth hormone of the tissues of the proliferative bone (bone). More preferably bone length growth.
- composition of the present invention contains the Chinese quince as an active ingredient, and is effective in promoting bone length growth and growth of growth plate cartilage tissue. This is illustrated well in the specification examples of the present invention.
- the change of growth plate tissue was observed. As a result, it was confirmed that the lengths of the growth plate prol i ferat ive zone and hyper t rophi c zone were increased to the level similar to that of the growth hormone administration group.
- the change in the number of activated chondrocytes in the chondrocytes was confirmed by BrdU staining. As a result, it was confirmed that the ratio of BrdU positiv cel l was increased, thereby promoting the proliferation of chondrocytes in the neck and the administration group.
- osteocalcin concentration in plasma was measured. As a result, it was confirmed that the concentration of osteocalcin in plasma was increased in neck and administration group. As a result, it was confirmed that the neck and extract increase osteogenic and osteoblast activity.
- the present invention provides a pharmaceutical composition for promoting growth comprising a Chinese quince as an active ingredient.
- the pharmaceutical composition according to the present invention may contain the Chinese quince tree of the present invention alone or may further contain one or more pharmaceutically acceptable carriers, excipients or diluents.
- pharmaceutically acceptable is a non-toxic composition that, when administered physiologically, does not inhibit the action of the active ingredient and does not normally cause allergic reactions such as gastrointestinal disorders, dizziness or similar reactions.
- Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration.
- Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like.
- peptides It may include various drug delivery materials used for oral administration of the formulation.
- carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose, glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutane.
- the pharmaceutical composition of the present invention may further include a lubricant wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspension agent, and the like in addition to the above components.
- a lubricant wetting agent e.g., a lubricant wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspension agent, and the like.
- Other pharmaceutically acceptable carriers and formulations may be referenced in the following literature (Remington's Pharmaceut i cal Sciences, 19th ed., Mack Publ i shing Company, East on, PA, 1995) .
- the composition of the present invention may be administered to any mammal, including humans. For example, it can be administered orally or parenterally.
- Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal topical, sublingual or rectal administration.
- the pharmaceutical composition of the present invention may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.
- compositions of the present invention may be formulated using methods known in the art as powder granules, tablets, pills, sugar tablets, capsulants, solutions, gels, syrups, slurries, suspensions and the like.
- oral formulations can be obtained by tablets or dragees by combining the active ingredient with a solid brother and then grinding it, adding suitable auxiliaries and processing it into a granular mixture.
- suitable excipients include sugars and corn starch, wheat starch, rice starch and potato starch, including lactose, textrose, sucrose, solbi, manny, xili, erysri and malty.
- Cellulose , gelatin, polyvinylpyridone and the like may be included, including starch
- crosslinked polyvinylpyridone, agar, alginic acid or sodium alginate may be added as a disintegrant.
- the pharmaceutical composition of the present invention may further include an anti-collar, a lubricant wetting agent, a fragrance, an emulsifier and a preservative.
- the total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol which is administered for a long time in multiple doses.
- the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease.
- the preferred total dose of the pharmaceutical composition of the present invention may be from about 0.01 / ⁇ to 10,000 mg, most preferably to lOOOOmg per patient body weight per day.
- the dosage of the pharmaceutical composition is determined by the various factors such as the age, weight, health status, sex, severity of the disease, diet and excretion rate, as well as the formulation method, route of administration and frequency of treatment. As such, those of ordinary skill in the art will be able to determine appropriate effective dosages of the compositions of this invention.
- a pharmaceutical composition according to the present invention is not particularly restricted in its dosage form i route of administration and method of administration shown by the effect of the present invention.
- the present invention provides a growth promoting food composition comprising a Chinese quince as an active ingredient.
- the food composition of the present invention is a functional food (functional food), nutritional supplements
- Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
- the Chinese quince tree of the present invention may be prepared in the form of tea, juice and drink for drinking or granulated, capsulated and powdered.
- the Chinese quince tree of the present invention can be prepared in the form of a composition by mixing with a known substance or active ingredient known to have a bone growth promoting effect.
- the food composition of the present invention may further contain trace minerals, vitamin lipids, sugars and components having known growth promoting activity, etc., in addition to the Chinese quince or Chinese quince extract component.
- the minerals may contain nutrients necessary for the growing season, such as calcium, iron, Vitamins may include vitamins ( ⁇ ) vitamin E, vitamin B1, vitamin B2, vitamin B6, etc.
- Lipids may contain alkoxyglycerol or lecithin, and sugars may contain fructooligosaccharides. have.
- functional foods include beverages (including alcoholic beverages), fruits and processed foods (female 1: canned fruit, canned jam, malade, etc.), fish, meat and processed foods (eg ham). Sausages and corn, etc.), breads and noodles (e.g. udon noodles, soba noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juices, cookies, sweets, dairy products (e.g. butter, cheese, etc.) It can be prepared by adding the Chinese quince tree of the present invention to vegetable protein, retort food, copper food, various seasonings (e.g., miso, soy sauce, sauce, etc.).
- the Chinese quince tree of the present invention in the form of a food additive, it may be prepared and used in the form of a powder or a concentrate.
- the content of the Chinese quince in the food composition of the present invention may be contained in a ratio of 0.0190%, preferably 0.150%, based on the total weight of the food based on the total weight of the food composition.
- the present invention is a composition for promoting animal growth comprising a Chinese quince as an active ingredient.
- the feed composition according to the present invention may be prepared in the form of fermented feed, blended feed, pellet form, and silage.
- the fermented feed includes the Chinese quince tree of the present invention, and may be prepared by fermenting an organic material by adding various microorganisms or enzymes.
- the blended feed may be prepared by mixing various kinds of general feed and the quince tree of the present invention.
- Pellet-type feed may be prepared by formulating the fermented feed or blended feed into a pellet machine.
- Silage can be prepared by mixing fertilizer feed and the Chinese quince tree of the present invention to ferment with lactic acid bacteria.
- the present invention provides the use of Chinese quince for the production of growth promoters.
- the present invention provides a use of the Chinese quince for producing a food composition for promoting growth.
- the present invention provides the use of Chinese quince for the production of animal feed for growth promotion. Ball.
- the present invention provides a method for promoting growth, comprising administering an effective amount of a Chinese quince to an individual in need of growth.
- the growth of the present invention means an increase in the size and function of each organ of the body, preferably the size, thickness, density, length of tissues of the proliferative bone (bone) increased function and growth hormone More preferably, it means the length of bone growth.
- the Chinese quince represents one or more selected from the group consisting of fruit, leaves, flowers, stems, and roots, and may be processed and used as it is or in form that can be administered to animals.
- the form that can be administered to the animal may be powder L suspension suspension, etc., preferably may be a Chinese quince extract.
- the Chinese quince extract may be extracted by a known natural product extraction method, preferably extracted with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, and subcritical or supercritical euse.
- the organic solvent having 1 to 6 carbon atoms may be 1 to 6 carbon atoms (al cohol), acetone (acetone), ether (ether), benzene (chloroform) chloroform, ethyl acetate (ethyl acetate) It may be selected from the group consisting of methylene chloride (methylene chloride), hexane (hexane), cyclonucleic acid (cyc l ohexane), diethyl ether and petroleum ether. Preferably it can be extracted using water or alcohol having 1 to 6 carbon atoms.
- a pharmaceutical composition comprising the Chinese quince tree as an active ingredient may be administered in various amounts, including oral, transdermal, subcutaneous, intravenous or intramuscular.
- the term "effective amount” refers to an amount indicating bone growth when administered to an individual, and the term “subj ect” may be an animal, preferably a mammal, particularly an animal including a human. The subject may be a growth patient in need of bone growth.
- the Chinese quince extract of the present invention may be administered as it is, or prepared and administered in various formulations as described above, and preferably, may be administered until a desired effect, that is, a growth effect, is derived.
- Chinese quince tree of the present invention as an active ingredient
- Including pharmaceutical compositions can be administered by a variety of routes according to methods known in the art. That is orally or parenterally, such as oral, intramuscular, intravenous, intradermal, intraarterial, intramedullary, intradural, intraperitoneal, intranasal, intravaginal, rectal, sublingual or subcutaneous, or into the gastrointestinal tract, mucosa or respiratory tract.
- composition comprising the Chinese quince tree as an active ingredient has an effect of promoting growth of growth plates and long bones, and is effective in promoting growth and skeletal formation of infants and adolescents during the growing season.
- composition of the present invention alone or in combination with growth hormone treatment is effective for the treatment of height growth.
- 1 is a diagram showing the change in weight of rats (rat) for 10 days for each administration group.
- Figure 2 shows the results of micro-CT imaging of rat tibia (tibia) for each administration group.
- Figure 3 shows the X-ray image of the rat tibia for each administration group.
- Figure 4 shows the total tibia length of the rat for each administration group (total tibia length).
- Figure 5 shows the location and relative length of the proliferative zone and hypertrophic zone in the growth plate of the rat for each administration group (control: saline administration group, GH: growth hormone administration group, neck and neck: neck and extract administration group) .
- FIG. 6 is a diagram showing the length of the proliferation zone (prol i ferative zone) in the growth plate (growth plate) area of each administration group (control: saline administration group, growth: growth hormone administration group, neck: neck and extract administration group).
- Figure 7 is a diagram showing the length of the hypertrophic zone of the growth plate (growth plate) area of each administration group (control: saline administration group, growth: growth hormone administration group, neck and neck: neck and extract administration group).
- Figure 8 shows the results of BrdU staining the cartilage tissue of each administration group as an image.
- Figure 9 shows the ratio of BrdU positive cells in the cartilage tissue of each administration group.
- Figure 10 shows the results of measuring the concentration of osteocalcin (osteocalcin) in the plasma in each administration group.
- the tree was purchased from Dongyang Pharmaceutical Co., Ltd.
- Three-week-old Male Sprague-Daw ley rats were purchased and stabilized for three days.
- the breeding environment was maintained at 24 ° C 2 ° C, and the light and dark cycles were kept for 12 hours, and the feed was used as a general solid feed without antibiotics.
- the control group was infused with sal ine, and the oral and extracts were orally administered once daily by oral administration (the neck and extract powder prepared in Example 1 was dissolved in water and administered).
- Eutropin LG Life Sciences
- rats are administered to oral cavi ty in all groups except the posi ive group, and all animals are administered once daily.
- the composition of each group is as follows.
- the volume and thickness of the trabecular bone associated with the bone density of the left tibia were confirmed by micro-CT examination.
- the volume and the thickness of the trabecular bone were measured using micro-CT.
- Mi cro— CT system uses SKYSCAN 1172 mi cro-CT device and X-ray source is 50kV, 200mA. The source and detector are fixed and the object rotates between them to obtain projection data. The image has a size of 0.8um-25um pixels.
- the ratio and thickness of trabeculae are calculated by reconstructing the volume ratio of trabecula (BV / TV,%) and bone thickness (Tb.Th, mm) inside the rectangle of the left femur in the 2D image.
- the fuzzy di stance transform (FDT) algorithm was applied (In Kon Chunl., Et al., In vivo trabecular thickness measurement in cancel lous bones: longi tudinal rat imaging studies. Phys iol. Meas. 27 (2006) ) 695-702) ⁇ 169>
- the left and right tibia (shalp bone) of the experimental group and the control group ingested the Chinese quince or radish extract according to the present invention is attached to the bone tissue All muscles, fats, ligaments, etc. were removed and stored in 70% alcohol and X-ray equipment (0M-F0RTE -10121 ⁇ DK Medical System) was used. X-ray source was 55kV, 320mA. Tibia length was measured by X-ray imaging of the tibia.
- growth hormones were increased compared to the control group.
- the total tibia length was increased in the other groups, and the total tibia length was also increased in the group treated with the neck compared to the control group.
- ⁇ i8i> The length of the growth plate zone is fixed by cartilage tissue after autopsy and stained by H & E staining technique, followed by microscopy. Measure the length of each zone 5 times per sample and use the averaged value as a representative value to evaluate the significance. ⁇ 182>
- the proliferative and hypertrophic zones of the growth hormone-administered group were increased compared to the control group, and the proliferative and hypertrophic zones of the neck and administration groups were also increased.
- the length increased significantly compared to the control group.
- rat tibial cartilage tissue was used and brdU staining was applied to S phase proliferative cells in the growth plate of this region.
- Sigma 5-Bromo-2-deoxyur idine Product No .: B9285
- NH 4 0H ammonium hydroxide
- Paraffin embedded tissues were fixed and stained by BrdU staining kit (Invitrogen, 93-3943). BrdU positive ceH was counted using a cell counter.
- the growth rate of BrdU positive cells was increased to a similar level in both the growth hormone group and the neck and administration groups compared to the control group. This indicates that the neck and the administration group have a chondrocyte proliferation effect.
- Rat blood was collected from the heart after administration and uncoated, and serum was isolated to make a sample.
- Rat Ostecalcin / Bone Gla Protein Rat Ostecalcin / Bone Gla Protein.
- Total osteocalcin levels in serum were measured using the OT / BGP EL ISA Kit (Cusabio, product number: CSB—E05129r).
- the plasma osteocalcin level was significantly increased in both the growth hormone administration group and the neck and extract administration group compared with the control group.
- the results of slightly higher levels of osteocalcin were found in the neck and administration groups compared to the growth hormone administration group. Osteocalcin is formed in osteoblasts and then deposited in the bone matrix, and some of the newly formed osteocalcin is released into the blood. Therefore, the level of bone formation can be determined by measuring blood levels. Concentrations are believed to reflect the activity of osteoblasts. It has been shown that the neck and extract of the present invention significantly increase the concentration of osteocalcin in plasma, resulting in increased bone formation and osteoblast activity.
- the present invention relates to a growth promoting effect of a Chinese quince, and more particularly to a pharmaceutical composition for promoting growth, a food composition and a composition for animal feed comprising the Chinese quince as an active ingredient.
- a pharmaceutical composition for promoting growth a food composition and a composition for animal feed comprising the Chinese quince as an active ingredient.
- composition comprising the Chinese quince of the present invention as an active ingredient has an effect of promoting growth of growth plates and iliac bone, and is effective in promoting growth and skeletal formation of infants and adolescents during the growing season, as well as the composition of the present invention. It is highly industrially available because it is effective for the treatment of height growth, either through or in combination with growth hormone therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a growth promotion effect of chaenomeles sinesis, and more specifically to a pharmaceutical composition for promoting growth, a food composition, and a composition for an animal feed comprising chaenomeles sinesis as an active ingredient. The composition of the present invention comprising chaenomeles sinesis as the active ingredient has an advantageous effect of promoting growth of a physeal plate and a long bone, and the composition of the present invention is effective in promoting a growth and a bone-forming of an infant and a juvenile in a growth period, and furthermore the composition of the present invention alone or with a parallel treatment of a growth hormone treatment has an advantageous effect of treating a stature growth.
Description
【명세서】 【Specification】
【발명의 명칭】 [Name of invention]
모과나무를 유효성분으로 포함하는 성장 촉진용 조성물 【기술분야】 Growth promoting composition containing Chinese quince as an active ingredient
<ι> 본 출원은 2014년 03월 28일에 출원된 대한민국 특허출원 제 10-2014-0036559 호를 우선권으로 주장하고, 상기 명세서 전체는 본 출원의 참고문헌이다. <ι> This application claims the priority of Korean Patent Application No. 10-2014-0036559, filed March 28, 2014, the entirety of which is a reference of the present application.
<2> <2>
<3> 본 발명은 모과나무의 성장 촉진 효과에 관한 것으로, 더욱 상세하게는 모과 나무를 유효성분으로 포함하는 성장 촉진용 약학적 조성물, 식품 조성물 및 동물 사료용 조성물에 관한 것이다. The present invention relates to a growth promoting effect of Chinese quince, and more particularly to a pharmaceutical composition for promoting growth, a food composition and a composition for animal feed comprising the Chinese quince as an active ingredient.
<4> <4>
【배경기술】 Background Art
<5> 최근 들어 체형의 서구화 및 평균 신장의 상승으로 인하여 키 성장인자에 대 한 관심이 높아지고 있다 . 성장을 광의의 개념으로 정의하면 신장의 증가뿐 아니라 신체 각 기관의 크기와 기능의 증대를 포함하는 것이라 할 것이나, 이를 협의의 개 념으로 정의하자면 신장의 증가를 의미하는 것으로 볼 수 있다. 이러한 신장의 증 가는 영양과 성장 호르몬 등의 여러 요인에 의한 연골 조직의 합성, 골격 길이 성 장 및 골격 조직의 광범위한 증식을 포함하는 골격대사를 통하여 이루어진다. 골( 뼈) 조직은 특수하게 분화된 형태의 결합 조직으로, 간엽세포, 연골세포, 조골세 포 파골세포, 골수세포 등 여러 종류의 세포로 구성된 결합조직이다. 파골세포에 의한 골흡수 양과 조골세포에 의한 골형성 양 사이에는 균형이 유지되고 있는데, 성장기에는 조골세포에 의한 골 형성 능력이 최고치에 이르러 골형성 양이 골흡수 양을 훨씬 능가하게 되므로 뼈 성장이 이루어지게 된다. <5> Recently, interest in height growth factors has increased due to the westernization of body shape and the increase in average height. If we define growth as a broad concept, it means not only an increase in height but also an increase in the size and function of each organ of the body, but a concept of consultation can mean an increase in height. This increase in kidney is achieved through skeletal metabolism, which involves the synthesis of cartilage tissue, skeletal length growth, and extensive proliferation of skeletal tissue by various factors such as nutrition and growth hormone. Bone (bone) tissue is a specially differentiated connective tissue, which is composed of several types of cells such as mesenchymal cells, chondrocytes, osteoblast osteoclasts, and bone marrow cells. There is a balance between the amount of bone resorption by osteoclasts and the amount of bone formation by osteoblasts. In the growth period, bone growth is greater than the amount of bone resorption by osteoblasts. Will be done.
<6> <6>
<7> 성장판 (growth pi ate)은 장골의 양단에 위치해 있는 수평적으로 정형화된 구 조를 지닌 연골세포집단으로서 뻐몸통끝 (metaphys i s)과 뼈끝 (epiphysi s ) 사이에 위 치하고 있다. 성장판 내 연골세포 (chondrocyte)의 증식 , 비대 (hypertrophy), 세포 외간질 (extrace l lul ar mat r ix) 분비, 혈관과 골전구세포의 침입과 이에 따른 골화 (oss i f i cat ion)과정을 거쳐 결국 연골이 골로 변화하게 되는 연골내 골화 (endochondral oss i f i cat ion) 과정을 거치면서, 성장판의 뼈몸통끝 부위에 새로운 골이 지속적으로 형성되고, 이에 따라 장골의 길이가 길어지게 된다. 성장판은 성
장호르몬, 인술리양 성장인자 ( insul in-l ike growth factor , IGF) , 갑상샘호르몬, 성 호르몬, 글루코코르티코이드 등의 호르몬과 여러 시토카인에 의해 조절을 받으며, 결국 사춘기 후에 골화되면서 주위 뼈와 융합된다 (신층호, 2006,호르몬의 성장판 조 절,대한소아내분비학회지ᅳ vol 11, 117-122) . The growth piate is a group of horizontally shaped cartilaginous cells located at both ends of the long bone, located between the metaphys is and the epiphysi s. After the growth of chondrocytes, growth of hypertrophy, secretion of extracellular epilepsy, invasion of blood vessels and bone precursor cells and oss ifi cat ion During the process of endochondral oss ifi cat ion where the cartilage is turned into bone, new bone is continuously formed at the end of the bone trunk of the growth plate, thereby lengthening the long bone. Growth plate is castle It is regulated by hormones such as intestinal hormone, insul in- ike growth factor (IGF), thyroid hormone, sex hormone, and glucocorticoids and various cytokines, which eventually become ossified and fuse with surrounding bones ( Shin, Ho-Ho, 2006, Hormone Growth Edition, Korean Society of Pediatric Endocrinology, vol 11, 117-122.
<8> <8>
<9> 한편, 지금까지 성장을 촉진시키기 위한 방법으로는 성장 호르몬 제제 투여 법, 일리자노프 수술법 및 건강보조식품 복용법 등이 사용되어 왔다. 특히 과거 병 적인 상태의 성장부진에 쓰이던 성장호르몬 요법이 근래에 키 성장에 대한 관심이 높아져감에 따라 정상 신장을 가지고 있는 성장기 어린이 및 청소년에게도 적용 되 고 있다. 그러나 상기 성장 호르몬 제제 투여법은 성장 호르몬이 부족한 사람의 경 우에는 뛰어난 효과를 보이지만, 호르몬 분비가 정상적인 대다수의 사람들에게는 말단 비대증 성장 호르몬 항체 양성, 전신 알레르기 반웅, 갑상선기능 저하증 등 의 여러 가지 부작용을 야기할 수 있는 문제점이 있다. 뿐만아니라 성장호르몬 요 법의 기간과 비용이 과도하고 암발생 및 다른 성장인자들의 교란을 일으키는 등의 문제점이 발견되고 있다. 또한, 일리자노프 수술은 다리의 뼈를 절단한 후 늘리는 수술로서 환자의 고통 및 비용 측면에서 일반인에게 사용하기에는 많은 무리가 있 으며, 성장 촉진용 건강보조식품은 과학적으로 검증되지 않은 경우가 대부분이다. <10> 따라세 성장 촉진에 있어서 그 효능이 과학적으로 검증되고, 안전한 식품소 재의 개발이 필요한 실정이다. Meanwhile, as a method for promoting growth, a growth hormone preparation administration method, an irizanov operation method, and a dietary supplement taking method have been used. In particular, growth hormone therapy, which has been used in the past for pathologically sluggish growth, has been applied to growing children and adolescents with normal kidneys as their interest in height growth has recently increased. However, the method of administration of the growth hormone preparation shows an excellent effect in the case of the lack of growth hormone, but the majority of people with normal hormone secretion have various side effects such as positive terminal hypertrophic growth hormone antibody, systemic allergic reaction, hypothyroidism, etc. There is a problem that can be caused. In addition, problems such as excessive duration and cost of growth hormone therapy, cancer, and disturbance of other growth factors have been found. In addition, ilizanov surgery is an operation that is performed after cutting the bone of the leg, and it is difficult to use it for the general public in terms of pain and cost of patients, and growth supplements are mostly scientifically untested. . <10> Therefore, the efficacy of promoting growth is scientifically verified and the development of safe food materials is required.
<1 1> <1 1>
【발명의 상세한 설명】 [Detailed Description of the Invention]
【기술적 과제】 [Technical problem]
<12> 이에 본 발명자들은 부작용 없이 성장을 효과적으로 촉진하는 활성을 가진 식품소재를 개발하고자 연구하던 중, 모과를 투여한 실험동물에서 성장판 촉진 및 장골 길이 증가 효과를 확인하고 본 발명을 완성하였다. The present inventors while studying to develop a food material having an activity that effectively promotes growth without side effects, confirmed the effect of growth plate promotion and iliac bone length increase in experimental animals administered quince and completed the present invention.
<13> <13>
<14> 따라서 본 발명의 목적은 모과나무를 유효성분으로 포함하는 성장 촉진용 약 학적 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a pharmaceutical composition for promoting growth comprising a Chinese quince as an active ingredient.
<15> <15>
< 16> 본 발명의 다른 목적은 모과나무를 유효성분으로 포함하는 성장 촉진용 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a growth promoting food composition comprising a Chinese quince as an active ingredient.
<17>
<18> 본 발명의 다른 목적은 모과나무를 유효성분으로 포함하는 성장 촉진용 동물 사료용 조성물을 제공하는 것이다. <17> Another object of the present invention to provide a composition for promoting animal feed comprising a Chinese quince as an active ingredient.
<19> <19>
<20> 본 발명의 다른 목적은 성장 촉진제 제조를 위한 모과나무의 용도를 제공하 는 것이다. Another object of the present invention is to provide the use of Chinese quince for the production of growth promoters.
<21 > <21>
<22> 본 발명의 다른 목적은 성장 촉진용 식품 조성물 제조를 위한 모과나무의 용 도를 제공하는 것이다. Another object of the present invention is to provide a use of Chinese quince for preparing a food composition for growth promotion.
<23> <23>
<24> 본 발명의 다른 목적은 성장 촉진용 동물 사료 제조를 위한 모과나무의 용도 를 제공하는 것이다. Another object of the present invention is to provide a use of Chinese quince for the production of animal feed for growth promotion.
<25> <25>
<26> 본 발명의 다른 목적은 성장을 필요로 하는 개체에 유효량의 모과나무를 투 여하는 것을 특징으로 하는 성장 촉진 방법을 제공하는 것이다. Another object of the present invention is to provide a method for promoting growth, comprising administering an effective amount of a Chinese quince to an individual in need of growth.
<27> <27>
【기술적 해결방법】 Technical Solution
<28> 상기의 목적을 달성하기 위하여, 본 발명은 모과나무를 유효성분으로 포함하 는 성장 촉진용 약학적 조성물을 제공한다. In order to achieve the above object, the present invention provides a pharmaceutical composition for growth promotion comprising a Chinese quince as an active ingredient.
<29> <29>
<30> 본 발명의 다른 목적을 달성하기 위하여, 본 발명은 모과나무를 유효성분으 로 포함하는 성장 촉진용 식품 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a food composition for growth promotion comprising a Chinese quince as an active ingredient.
<31> <31>
<32> 본 발명의 다른 목적을 달성하기 위하여 , 본 발명은 모과나무를 유효성분으 로 포함하는 성장 촉진용 동물 사료용 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a composition for promoting animal feed comprising a Chinese quince as an active ingredient.
<33> <33>
<34> 본 발명의 다른 목적을 달성하기 위하여, 본 발명은 성장 촉진제 제조를 위 한 모과나무의 용도를 제공한다. In order to achieve another object of the present invention, the present invention provides the use of a Chinese quince tree for the production of growth promoters.
<35> <35>
<36> 본 발명의 다른 목적을 달성하기 위하여, 본 발명은 성장 촉진용 식품 조성 물 제조를 위한 모과나무의 용도를 제공한다. In order to achieve another object of the present invention, the present invention provides the use of the Chinese quince for producing a food composition for promoting growth.
<37> <37>
<38> 본 발명의 다른 목적을 달성하기 위하여, 본 발명은 성장 촉진용 동물 사료
제조를 위한 모과나무의 용도를 제공한다ᅳ 본 발명의 다른 목적을 달성하기 위하여 , 본 발명은 성장을 필요로 하는 개 체에 유효량의 모과나무를 투여하는 것을 특징으로 하는 성장 촉진 방법을 제공한 다. 이하 본 발명을 상세히 설명한다 . 본 발명은 모과나무를 유효성분으로 포함하는 성장 촉진용 조성물을 제공한 다. 모과나무 (qui nce t ree , Chaenomeles sinensisᅳ)는 쌍떡잎식물 장미목 장미과 의 낙엽교목으로, Cydonia sinensis, Pseudocydonia sinensis, Cydonia sinensis, Cydonia oblonga등의 여러 이명을 가진다. 본 발명의 모과나무는 모과나무를 구성하는 부위라면 어디든지 제한되지 않 지만, 바람직하게 모과나무의 열매 잎, 꽃, 줄기 및 뿌리로 이루어진 군에서 선택 된 하나 이상의 것 일 수 있으며, 더욱 바람직하게는 모과나무 열매 일 수 있다. 상기 모과나무의 열매는 독^ Chaenomelis Fructus, 木瓜)라는 생약명으로 주로 불리우며, 상기 목과는 모과, 모과실, 목과실, 향과, 해당ᅵ 목이, 모개, 철각 리 등으로도 불리우며, 본 발명의 명세서에 있어서 상기 용어들을 흔용하여 지칭할 수 있다. ― 본 발명의 모과나무는 그대로 또는 동물에게 투여 가능한 형태로 가공되어 사용될 수 있으며, 이에 제한되지 않으나 예를 들어 분말, 현탁액 추출물 등일 수 있고 바람직하게 모과나무 추출물일 수 있다ᅳ 상기 모과나무 추출물은 공지의 천연물 추출방법에 의하여 추출될 수 있으 며, 바람직하게는 물, 탄소수 1 내지 6개의 유기용매 및 아임계 또는 초임계 유체 로 이루어진 군에서 선택된 하나 이상의 용매로 추출될 수 있으며, 상기 탄소수 1 내지 6개의 유기용매는 탄소수 1 내지 6개의 알코을 ( al coho l ) , 아세톤 ( acetone ),
에테르 (ether ) , 벤젠 (benzene) , 클로로포름 (chloroform) , 에틸아세테이트 (ethyl acetate) , 메틸렌클로라이드 (methylene chloride) , 핵산 (hexane) , 시클로헥산 (cyclohexane) , 디에틸에테르 (diethyl ether ) 및 석유에테르 (petroleum ether )로 이루어진 군 중에서 선택된 것일 수 있다. 바람직하게 물 또는 탄소수 1 내지 6개 의 알코을을 사용하여 추출할 수 있다. In order to achieve another object of the present invention, the present invention provides a feed for promoting animal growth Provided is the use of Chinese quince for manufacturing. In order to achieve another object of the present invention, the present invention provides a method for promoting growth, comprising administering an effective amount of a Chinese quince to an object in need of growth. . Hereinafter, the present invention will be described in detail. The present invention provides a growth promoting composition comprising a Chinese quince as an active ingredient. The quince tree (qui nce t ree, Chaenomeles sinensis ᅳ) is a deciduous tree of the dicotyledonous rosacea rosaceae, which has several aliases such as Cydonia sinensis, Pseudocydonia sinensis, Cydonia sinensis, and Cydonia oblonga. The Chinese quince tree of the present invention is not limited to any part constituting the Chinese quince, but preferably may be one or more selected from the group consisting of fruit leaves, flowers, stems and roots of the Chinese quince, more preferably It can be a quince fruit. The fruit of the Chinese quince tree is mainly called the herbal name Chaenomelis Fructus, 木瓜), the tree family is also called quince, quince, tree fruit, incense, and the corresponding neck, hairpin , iron shell , etc., specification of the present invention In the above, the above terms may be commonly used. The Chinese quince tree of the present invention can be processed or used as it is or in a form that can be administered to an animal, but is not limited thereto, and may be, for example, a powder, a suspension extract, and the like. It may be extracted by a natural product extraction method of, preferably water, may be extracted with one or more solvents selected from the group consisting of 1 to 6 carbon atoms organic solvent and subcritical or supercritical fluid, Organic solvents include alcohols, acetone, Ether, benzene, chloroform, ethyl acetate, methylene chloride, nucleic acid, cyclohexane, diethyl ether and petroleum ether It may be selected from the group consisting of (petroleum ether). Preferably it can be extracted using water or alcohol having 1 to 6 carbon atoms.
<55> 상기 모과나무 추출물은 추출효율을 증대시키기 위해 전처리 과정을 포함할 수 있으며 예를 들어 모과나무를 분쇄기로 분쇄하여 사용할 수 있다. The Chinese quince extract may include a pretreatment process to increase the extraction efficiency, for example, may be used by grinding the Chinese quince with a grinder.
<56> <56>
<57> 본 발명의 추출물 추출온도는 특별히 제한되지 아니하며, 예를 들어 0°C 내 지 15C C일 수 있으며, 바람직하게는 80°C 내지 120°C일 수 있다. 본 발명의 추출 물 추출시간은 추출 은도에 따라 특별히 제한되지 아니하며 , 예를 들어 10분 내지 10일 일 수 있으며 , 바람직하게는 30분 내지 24시간 일 수 있으며, 더욱 바람직하 게는 1시간 내지 6시간 일 수 있다. Extraction temperature of the extract of the present invention is not particularly limited, and may be, for example, 0 ° C to 15 C C, preferably 80 ° C to 120 ° C. Extraction time of the extract of the present invention is not particularly limited depending on the degree of extraction silver, for example may be 10 minutes to 10 days, preferably 30 minutes to 24 hours, more preferably from 1 hour to 6 It can be time.
<58> <58>
<59> 본 발명 추출물은 공지의 천연물 추출법으로 추출될 수 있다. 예를 들어 넁 침추출, 열수추출, 초음파 추출ᅳ 환류넁각 추출, 가열 추출법으로 추출할 수 있으 몌 바람직하게는 열수추출 또는 환류 넁각 추출법으로 추출할 수 있으며, 1회 내 지 10회 , 바람직하게는 2회 내지 7회 반복 추출할 수 있다. Extract of the present invention can be extracted by known natural product extraction method. For example, it can be extracted by 넁 acupuncture extraction, hot water extraction, ultrasonic extraction ᅳ reflux 넁 angle extraction, heating extraction 몌 preferably can be extracted by hot water extraction or reflux 넁 angle extraction method, once to 10 times, preferably The extraction can be repeated two to seven times.
<60> <60>
<61> 또한 본 발명의 모과나무 추출물의 제조시 처리, 보관 등의 용이함을 위하여 여과 과정, 농축 및 정제과정 건조과정, 동결과정, 분말화 과정이 임의로 추가될 수 있다. In addition, a filtration process, a concentration and purification process, a drying process, a freezing process, and a powdering process may be arbitrarily added for ease of treatment, storage, and the like during the preparation of the Chinese quince extract of the present invention.
<62> <62>
<63> 상기 여과 과정은 공지의 여과 방법에 의할 수 있으며 이에 제한되지 않으 나 예를 들어 여과망 또는 마이크로필터를 이용한 여과, 원심분리 및 분액깔때기 를 이용할 수 있다. The filtration process may be based on a known filtration method, but is not limited thereto. For example, filtration, centrifugation, and separatory funnel using a filtration network or a micro filter may be used.
<64> <64>
<65> 상기 농축 과정은 공지의 농축 방법에 의할 수 있으며 이에 제한되지는 않으 나, 예를 들어 침전농축, 증발농축, 감압농축, 한의여과법, 역삼투법 및 원심분리 법을 이용하여 농축할 수 있다. 상기 농축과정에서 농축 농도는 고형분의 함량을 기준으로 3 내지 50 중량 %가 바람직하며, 더 바람직하게는 10 내지 20 중량 %의 농 도로 농축할 수 있으며, 가장 바람직하게는 14 내지 16중량 %의 농도로 농축 할 수
있다. The concentration process may be performed by a known concentration method, but is not limited thereto. For example, the concentration process may be concentrated using precipitation concentration, evaporation concentration, reduced pressure concentration, oriental filtration, reverse osmosis, and centrifugation. . In the concentration process, the concentration is preferably 3 to 50% by weight, more preferably 10 to 20% by weight, and most preferably 14 to 16% by weight, based on the amount of solids. Can be enriched with have.
<66> 상기 고형분이란 추출물의 용매를 모두 증발시켰을 때 남는 유효성분을 의미 하는 것으로, 본원 발명에서는 가용성 (solubl e) 고형분 및 비가용성 고형분을 모두 포함한다. The solids means an active ingredient remaining when all the solvents of the extract are evaporated, and the present invention includes both soluble solids and insoluble solids.
<67> <67>
<68> 상기 건조 과정은 공지의 건조 방법에 의할 수 있으며 이에 제한되지 아니 하나, 예를 들어 동결 건조, 분무 건조 또는 열풍건조 일 수 있다. The drying process may be by a known drying method, but is not limited thereto, and may be, for example, freeze drying, spray drying, or hot air drying.
<69> 또한 분말화 과정은 공지의 분말화 방법에 의할 수 있으며 이에 제한되지 아 니하나, 예를 들어 덱스트린 포접 등의 과정에 의해 분말화 될 수 있다. 바람직하 게 본원 발명의 추출물은 불활성 부형제로서 결정 샐를로오스를 첨가하여 열풍 건 조 하는 방법에 의해 분말화 될 수 있다. 상기 결정 셀를로오스의 첨가 비율은 고 형분 중량 기준으로 1 : 0. 1 내지 10의 비율로 첨가 될 수 있으며, 바람직하게 1 : 0. 1 내지 5일 수 있으며, 가장 바람직하게 1 : 0.5 내지 2 일 수 있다. In addition, the powdering process may be by a known powdering method, but is not limited thereto, for example, it may be powdered by a process such as dextrin inclusion. Preferably, the extract of the present invention may be powdered by the method of hot air drying by adding crystalline salose as an inert excipient. The addition rate of the crystalline cell may be added in a ratio of 1: 1 to 10, based on the solid content weight, preferably 1: 0.1 to 5, and most preferably 1: 0.5 to 2 Can be.
<70> <70>
<71> 본 발명의 가장 바람직한 실시형태는 목과 (木瓜) 추출물이다. The most preferred embodiment of the present invention is an extract of the neck family.
<72> 상기 목과 추출물은 이에 제한되지 않으나, 바람직하게 물을 용매로 이용하 여 열수 추출방법에 의해 제조될 수 있다. 상기 열수 추출시 목과와 물의 비율은 특별히 한정되지 않으나, 목과에 물을 3배~20배 (증량기준)로 첨가할 수 있다. 바람 직하게는, 추출효을을 증가시키기 위해서 목과에 대하여 물을 15배 -19배 (중량기준) 로 첨가할 수 있다. The neck and extracts are not limited thereto, and preferably, may be prepared by a hot water extraction method using water as a solvent. The ratio of neck and water during the extraction of hot water is not particularly limited, but water may be added to the neck 3 times to 20 times (increase). Preferably, water can be added 15-19 times (by weight) to the tree to increase the extraction effect.
<73> 본 발명의 일 실시예에서, 본 발명의 모과나무 추출물은 20~40mesh의 크기로 분쇄한 목과 600g에 물 10L를 넣고 10C C에서 2시간씩 2회 열수 추출하였다. 상기 열수 추출액을 상은에 방치하여 식힌 후에 여과하여, 연조액스 전 단계로 고형분이 15중량 % 될 때까지 농축하고, 상기 농축액에 결정 셀를로오스를 흔합 및 건조하여 목과 추출물 분말을 제조하였다. In one embodiment of the present invention, the Chinese quince extract of the present invention was put into 10L of water and 600g crushed to the size of 20-40 mesh and extracted with hot water twice at 10C C for 2 hours. The hot water extract was left to cool to cool, filtered and concentrated until the solid content was 15% by weight in the pre-softening phase, and the crystalline cells were mixed and dried in the concentrate to prepare neck and extract powder.
<74> <74>
<75> 본 발명의 상기성장이란 신체 각 기관의 크기와 기능의 증대를 의미하며, 바 람직하게는 증식골 (뼈)의 조직의 크기, 굵기, 밀도, 길이, 기능 증대 및 성장호르 몬 증가를 포함하며 , 더욱 바람직하게는 골의 길이 성장을 의미한다 . The growth of the present invention refers to an increase in the size and function of each organ of the body, and preferably to increase the size, thickness, density, length, function increase and growth hormone of the tissues of the proliferative bone (bone). More preferably bone length growth.
<76> <76>
<77> 본 발명의 조성물은 모과나무를 유효성분으로 포함하며, 골 길이 성장 및 성 장판 연골조직 증식 촉진에 효과적이다.
<79> 이는 본 발명의 명세서 실시예에 잘 나타나있다. The composition of the present invention contains the Chinese quince as an active ingredient, and is effective in promoting bone length growth and growth of growth plate cartilage tissue. This is illustrated well in the specification examples of the present invention.
<80> <80>
<8i> 본 발명의 일실시예에서는 랫트 (rat )에 10일간 목과를 투여한 후, 경골 <8i> In one embodiment of the present invention, after administering the neck and neck to rats for 10 days, the tibia
( t i b i a)의 길이 변화를 관찰 하였다. 그 결과 성장호르몬 투여군과 비슷한 수준으 로 경골의 길이가 길어진 것을 확인하였다. The change in length of (t i b i a) was observed. As a result, the length of the tibia was confirmed to be similar to that of the growth hormone administration group.
<82> 본 발명의 또 다른 일실시예에서는 랫트 ( rat )에 10일간 목과를 투여한 후, 성장판 조직의 변화를 관찰하였다. 그 결과 성장판의 prol i ferat ive zone 및 hyper t rophi c zone의 길이가 성장 호르몬 투여군과 비슷한 수준으로 증가됨을 확인 하였다. In another embodiment of the present invention, after administration of the neck and the neck to rats for 10 days, the change of growth plate tissue was observed. As a result, it was confirmed that the lengths of the growth plate prol i ferat ive zone and hyper t rophi c zone were increased to the level similar to that of the growth hormone administration group.
<83> 본 발명의 또 다른 실시예에서는 랫트 (rat )에 10일간 목과를 투여한 후, 연 골조직에서 활성화된 연골 세포수의 변화를 BrdU staining으로 확인하였다. 그 결 과 BrdU posi t ive cel l 비을이 증가된 것을 확인하였고, 이로써 목과 투여군에서 연골세포증식이 촉진됨을 확인하였다. In another embodiment of the present invention, after administration of the neck and the rat for 10 days, the change in the number of activated chondrocytes in the chondrocytes was confirmed by BrdU staining. As a result, it was confirmed that the ratio of BrdU positiv cel l was increased, thereby promoting the proliferation of chondrocytes in the neck and the administration group.
<84> 본 발명의 또 다른 실시예에서는 ¾트(^ 에 10일간 목과를 투여한 후, 혈 장 속의 오스테오칼신 (osteocalcin) 농도를 측정하였다. 그 결과 목과 투여군에서 혈장 속 오스테오칼신 농도가 증가된 것을 확인하였고, 이로써 목과 추출물이 골형 성 및 골아세포 활성을 증가시키는 것을 확인하였다. In another embodiment of the present invention, after administering neck and neck for 10 days at ¾ (^), osteocalcin concentration in plasma was measured. As a result, it was confirmed that the concentration of osteocalcin in plasma was increased in neck and administration group. As a result, it was confirmed that the neck and extract increase osteogenic and osteoblast activity.
<85> <85>
<86> 따라서 본 발명은 모과나무를 유효성분으로 포함하는 성장 촉진용 약학적 조 성물을 제공한다. Therefore, the present invention provides a pharmaceutical composition for promoting growth comprising a Chinese quince as an active ingredient.
<87> <87>
<88> 본 발명에 따른 약학적 조성물은 본 발명의 모과나무를 단독으로 함유하거나 또는 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 함유할 수 있다. 상기에서 "약학적으로 허용되는" 이란 생리학적으로 허용되고 인간에게 투여될 때, 활성성분의 작용을 저해하지 않으며 통상적으로 위장 장애 , 현기증과 같은 알레르기 반웅 또는 이와 유사한 반웅을 일으키지 않는 비독성의 조성물을 말 한다. The pharmaceutical composition according to the present invention may contain the Chinese quince tree of the present invention alone or may further contain one or more pharmaceutically acceptable carriers, excipients or diluents. As used herein, "pharmaceutically acceptable" is a non-toxic composition that, when administered physiologically, does not inhibit the action of the active ingredient and does not normally cause allergic reactions such as gastrointestinal disorders, dizziness or similar reactions. Say.
<89> <89>
<90> 약학적으로 허용되는 담체로는 예컨대, 경구 투여용 담체 또는 비경구 투여 용 담체를 추가로 포함할 수 있다. 경구 투여용 담체는 락토스, 전분, 셀를로스 유 도체, 마그네슴 스테아레이트, 스테아르산 등을 포함할 수 있다. 아울러, 펩티드
제제에 대한 경구투여용으로 사용되는 다양한 약물전달물질을 포함할 수 있다. 또 한, 비경구 투여용 담체는 물, 적합한 오일, 식염수, 수성 글루코오스 및 글리콜 등을 포함할 수 있으며, 안정화제 및 보존제를 추가로 포함할 수 있다. 적합한 안 정화제로는 아황산수소나트륨, 아황산나트륨 또는 아스코르브산과 같은 항산화제가 있다. 적합한 보존제로는 벤즈알코늄 클로라이드, 메틸- 또는 프로필-파라벤 및 클 로로부탄을이 있다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제 습윤 제, 감미제, 향미제, 유화제, 현택제 등을 추가로 포함할 수 있다. 그 밖의 약학적 으로 허용되는 담체 및 제제는 다음의 문헌에 기재되어 있는 것을 참고로 할 수 있 다 (Remington ' s Pharmaceut i cal Sciences , 19th ed. , Mack Publ i shing Company , East on, PA, 1995) . 본 발명의 조성물은 인간을 비롯한 포유동물에 어떠한 방법으로도 투여할 수 있다. 예를 들면 경구 또는 비경구적으로 투여할 수 있다. 비경구적인 투여방법으 로는 이에 한정되지는 않으나, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관 국소, 설하 또는 직장내 투여일 수 있다. 본 발명의 약학적 조성물은 상술한 바와 같은 투여 경로에 따라 경구 투여용 또는 비경구 투여용 제제로 제형화 할 수 있다. Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. In addition, peptides It may include various drug delivery materials used for oral administration of the formulation. In addition, carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose, glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutane. The pharmaceutical composition of the present invention may further include a lubricant wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspension agent, and the like in addition to the above components. Other pharmaceutically acceptable carriers and formulations may be referenced in the following literature (Remington's Pharmaceut i cal Sciences, 19th ed., Mack Publ i shing Company, East on, PA, 1995) . The composition of the present invention may be administered to any mammal, including humans. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal topical, sublingual or rectal administration. Can be. The pharmaceutical composition of the present invention may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.
경구 투여용 제제의 경우에 본 발명의 조성물은 분말 과립, 정제, 환제, 당 의정제, 캡술제, 액제, 겔제, 시럽제, 슬러리제, 현탁액 등으로 당업계에 공지된 방법을 이용하여 제형화될 수 있다. 예를 들어, 경구용 제제는 활성성분을 고체 부 형제와 배합한 다음 이를 분쇄하고 적합한 보조제를 첨가한 후 과립 흔합물로 가공 함으로써 정제 또는 당의정제를 수득할 수 있다. 적합한 부형제의 예로는 락토즈, 텍스트로즈, 수크로즈, 솔비를, 만니를, 자일리를, 에리스리를 및 말티를 등을 포 함하는 당류와 옥수수 전분, 밀 전분, 쌀 전분 및 감자 전분 등을 포함하는 전분 류ᅵ 셀를로즈,메틸 셀를로즈, 나트륨 카르복시메틸셀를로오즈 및 하이드록시프로필 메틸-셀를로즈 등을 포함하는 셀를로즈류, 젤라틴, 폴리비닐피를리돈 등과 같은 충 전제가 포함될 수 있다. 또한 경우에 따라 가교결합 폴리비닐피를리돈, 한천, 알 긴산 또는 나트륨 알기네이트 등을 붕해제로 첨가할 수 있다. 나아가, 본 발명의 약학적 조성물은 항웅집게, 윤활제 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다. In the case of preparations for oral administration, the compositions of the present invention may be formulated using methods known in the art as powder granules, tablets, pills, sugar tablets, capsulants, solutions, gels, syrups, slurries, suspensions and the like. Can be. For example, oral formulations can be obtained by tablets or dragees by combining the active ingredient with a solid brother and then grinding it, adding suitable auxiliaries and processing it into a granular mixture. Examples of suitable excipients include sugars and corn starch, wheat starch, rice starch and potato starch, including lactose, textrose, sucrose, solbi, manny, xili, erysri and malty. Cellulose , gelatin, polyvinylpyridone and the like may be included, including starch | cells , methyl cellulose , sodium carboxymethyl cellulose and hydroxypropyl methyl-cellulose. In some cases, crosslinked polyvinylpyridone, agar, alginic acid or sodium alginate may be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anti-collar, a lubricant wetting agent, a fragrance, an emulsifier and a preservative.
비경구 투여용 제제의 경우에는 주사제, 크림제, 로션제, 외용연고제 오일
제, 보습제, 겔제, 에어로졸 및 비강 흡입제의 형태로 당업계에 공지된 방법으로 제형화할 수 있다. 이들 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문In the case of parenteral preparation, injection, cream, lotion, external ointment oil Formulations, moisturizers, gels, aerosols and nasal inhalants can be formulated by methods known in the art. These formulations are statements that are commonly known prescriptions for all pharmaceutical chemistry.
¾ (Remington ' s Pharmaceutical Science, 19th ed. , Mack Publishing Company , Easton, PA, 1995)에 기재되어 있다. ¾ (Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, PA, 1995).
<97> <97>
<98> 본 발명의 조성물의 총 유효량은 단일 투여량 (single dose)으로 환자에게 투여될 수 있으며ᅳ 다중 투여량 (multiple dose)으로 장기간 투여되는 분할 치료 방 법 (fractionated treatment protocol)에 의해 투여될 수 있다. 본 발명의 약학적 조성물은 질환의 정도에 따라 유효성분의 함량을 달리할 수 있다. 바람직하게 본 발명의 약학적 조성물의 바람직한 전체 용량은 1일당 환자 체중 1 당 약 0.01/^ 내 지 10,000mg, 가장 바람직하게는 내지 lOOOmg일 수 있다. 그러나 상기 약학 적 조성물의 용량은 제제화 방법, 투여 경로 및 치료 횟수뿐만 아니라 환자의 연 령, 체중 건강 상태, 성별, 질환의 중증도, 식이 및 배설율등 다양한 요인들을 고 려하여 환자에 대한 유효 투여량이 결정되는 것이므로, 이러한 점을 고려할 때 당 분야의 통상적인 지식을 가진 자라면 본 발명의 조성물의 적절한 유효 투여량을 결 정할 수 있을 것이다. 본 발명에 따른 약학적 조성물은 본 발명의 효과를 보이는 한 그 제형ᅵ 투여 경로 및 투여 방법에 특별히 제한되지 아니한다. The total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol which is administered for a long time in multiple doses. Can be. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease. Preferably the preferred total dose of the pharmaceutical composition of the present invention may be from about 0.01 / ^ to 10,000 mg, most preferably to lOOOOmg per patient body weight per day. However, the dosage of the pharmaceutical composition is determined by the various factors such as the age, weight, health status, sex, severity of the disease, diet and excretion rate, as well as the formulation method, route of administration and frequency of treatment. As such, those of ordinary skill in the art will be able to determine appropriate effective dosages of the compositions of this invention. A pharmaceutical composition according to the present invention is not particularly restricted in its dosage form i route of administration and method of administration shown by the effect of the present invention.
<99> <99>
<100> 본 발명은 모과나무를 유효성분으로 포함하는 성장 촉진용 식품 조성물을 제 공한다. The present invention provides a growth promoting food composition comprising a Chinese quince as an active ingredient.
<101> <101>
<102> 본 발명의 식품 조성물은 기능성 식품 (functional food), 영양 보조제 <102> The food composition of the present invention is a functional food (functional food), nutritional supplements
(nutritional supplement), 건강식품 (health food) 및 식품 첨가제 (food additives) 등의 모든 형태를 포함한다. 상기 유형의 식품 조성물은 당 업계에 공 지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. It includes all forms such as nutritional supplements, health foods and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
<103> 예를 들면 건강식품으로는 본 발명의 모과나무를 차, 쥬스 및 드링크의 형 태로 제조하여 음용하도록 하거나 과립화, 캡슬화 및 분말화 하여 섭취할 수 있 다. 또한, 본 발명의 모과나무를 골성장 촉진 효과가 있다고 알려진 공지의 물질 또는 활성 성분과 함께 흔합하여 조성물의 형태로 제조할 수 있다. 예를 들어 본 발명의 식품 조성물은 모과나무 또는 모과나무 추출물 성분 이외에 미량의 미네랄, 비타민 지질, 당류 및 공지의 성장촉진 활성을 가진 성분 등을 추가로 함유할 수 있다. 상기 미네랄로는 칼슘, 철 등 성장기에 필요한 영양성분이 함유될 수 있으며
비타민으로는 비타민 (:ᅳ 비타민 E, 비타민 B1, 비타민 B2, 비타민 B6 등이 함유될 수 있다. 지질로는 알콕시글리세를 또는 레시틴 등이 함유될 수 있으며 당류로는 프락토올리고당 등이 함유될 수 있다. For example, as a health food, the Chinese quince tree of the present invention may be prepared in the form of tea, juice and drink for drinking or granulated, capsulated and powdered. In addition, the Chinese quince tree of the present invention can be prepared in the form of a composition by mixing with a known substance or active ingredient known to have a bone growth promoting effect. For example, the food composition of the present invention may further contain trace minerals, vitamin lipids, sugars and components having known growth promoting activity, etc., in addition to the Chinese quince or Chinese quince extract component. The minerals may contain nutrients necessary for the growing season, such as calcium, iron, Vitamins may include vitamins (ᅳ) vitamin E, vitamin B1, vitamin B2, vitamin B6, etc. Lipids may contain alkoxyglycerol or lecithin, and sugars may contain fructooligosaccharides. have.
<104> <104>
<105> 또한, 기능성 식품으로는 음료 (알콜성 음료 포함), 과실 및 그의 가공식품( 여 1: 과일통조림, 병조림ᅳ 잼, 마아말레이드 등), 어류, 육류 및 그 가공식품 (예: 햄 소시지콘비이프 등), 빵류 및 면류 (예: 우동, 메밀국수, 라면, 스파게티, 마카 로니 등), 과즙 각종 드링크, 쿠키ᅳ 엿, 유제품 (예: 버터, 치이즈 등), 식용식물 유지, 마아가린, 식물성 단백질, 레토르트 식품, 넁동식품, 각종 조미료 (예: 된장, 간장, 소스 등) 등에 본 발명의 모과나무를 첨가하여 제조할 수 있다. In addition, functional foods include beverages (including alcoholic beverages), fruits and processed foods (female 1: canned fruit, canned jam, mamalade, etc.), fish, meat and processed foods (eg ham). Sausages and corn, etc.), breads and noodles (e.g. udon noodles, soba noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juices, cookies, sweets, dairy products (e.g. butter, cheese, etc.) It can be prepared by adding the Chinese quince tree of the present invention to vegetable protein, retort food, copper food, various seasonings (e.g., miso, soy sauce, sauce, etc.).
<106> 또한, 본 발명의 모과나무를 식품 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다. In addition, in order to use the Chinese quince tree of the present invention in the form of a food additive, it may be prepared and used in the form of a powder or a concentrate.
<107> <107>
<108> 본 발명의 식품 조성물 중 모과나무의 바람직한 함량은 식품 조성물 총 중량 에 대하여 식품의 전체 중량을 기준으로 0.0190%, 바람직하게는 0.150%의 비율로 함유될 수 있다. The content of the Chinese quince in the food composition of the present invention may be contained in a ratio of 0.0190%, preferably 0.150%, based on the total weight of the food based on the total weight of the food composition.
<109> <109>
<110> 본 발명은 모과나무를 유효성분으로 포함하는 성장 촉진용 동물 사료용 조성. The present invention is a composition for promoting animal growth comprising a Chinese quince as an active ingredient.
물을 제공한다. Provide water.
<111> <111>
<112> 본 발명에 따른 사료용 조성물은 발효사료, 배합 사료, 펠렛형태 및 사일레 지 (si lage) 등의 형태로 제조될 수 있다. 상기 발효사료 는 본 발명의 모과나무를 포함하고, 추가적으로 여러 가지 미생물 균 또는 효소들을 첨가함으로써 유기물을 발효시켜 제조될 수 있다. 상기 배합사료는 여러 종류의 일반 사료와 본 발명의 모 과나무 를 흔합하여 제조될 수 있다. 펠렛 형태의 사료는 상기 발효사료 또는 배합 사료를 펠렛기로 제형화하여 제조될 수 있다. 사일레지는 청예사료와 본 발명의 모 과나무를을 흔합하여 유산균으로 발효시킴으로서 제조될 수 있다. The feed composition according to the present invention may be prepared in the form of fermented feed, blended feed, pellet form, and silage. The fermented feed includes the Chinese quince tree of the present invention, and may be prepared by fermenting an organic material by adding various microorganisms or enzymes. The blended feed may be prepared by mixing various kinds of general feed and the quince tree of the present invention. Pellet-type feed may be prepared by formulating the fermented feed or blended feed into a pellet machine. Silage can be prepared by mixing fertilizer feed and the Chinese quince tree of the present invention to ferment with lactic acid bacteria.
<113> <113>
<114> 본 발명은 성장 촉진제 제조를 위한 모과나무의 용도를 제공한다. The present invention provides the use of Chinese quince for the production of growth promoters.
<115> 또한, 본 발명은 성장 촉진용 식품 조성물 제조를 위한 모과나무의 용도를 제공한다. In addition, the present invention provides a use of the Chinese quince for producing a food composition for promoting growth.
<116> 또한, 본 발명은 성장 촉진용 동물 사료 제조를 위한 모과나무의 용도를 제
공한다. In addition, the present invention provides the use of Chinese quince for the production of animal feed for growth promotion. Ball.
<1 17> 또한, 본 발명은 성장을 필요로 하는 개체에 유효량의 모과나무를 투여하는 것을 특징으로 하는 성장 촉진 방법을 제공한다. In addition, the present invention provides a method for promoting growth, comprising administering an effective amount of a Chinese quince to an individual in need of growth.
<1 18> <1 18>
<1 19> 본 발명의 상기성장이란 신체 각 기관의 크기와 기능의 증대를 의미하며, 바 람직하게는 증식골 (뼈)의 조직의 크기, 굵기, 밀도, 길이ᅵ 기능 증대 및 성장호르 몬 증가를 포함하몌 더욱 바람직하게는 골의 길이 성장을 의미한다. <1 19> The growth of the present invention means an increase in the size and function of each organ of the body, preferably the size, thickness, density, length of tissues of the proliferative bone (bone) increased function and growth hormone More preferably, it means the length of bone growth.
<120> <120>
<121> 상기 모과나무는 열매, 잎, 꽃, 줄기 및 뿌리로 이루어진 군에서 선택된 하 나 이상을 나타내며, 모과나무 그대로 또는 동물에게 투여 가능한 형태로 가공되어 사용될 수 있다. 이에 제한되지 않으나 동물에게 투여 가능한 형태로는 분말ᅵ 현탁 액 추출물 등일 수 있고, 바람직하게 모과나무 추출물일 수 있다. The Chinese quince represents one or more selected from the group consisting of fruit, leaves, flowers, stems, and roots, and may be processed and used as it is or in form that can be administered to animals. Although not limited thereto, the form that can be administered to the animal may be powder L suspension suspension, etc., preferably may be a Chinese quince extract.
<122> <122>
<123> 상기 모과나무 추출물은 공지의 천연물 추출방법에 의하여 추출될 수 있으 며, 바람직하게는 물, 탄소수 1 내지 6개의 유기용매 및 아임계 또는 초임계 유쎄 로 이루어진 군에서 선택된 하나 이상의 용매로 추출될 수 있으며, 상기 탄소수 1 내지 6개의 유기용매는 탄소수 1 내지 6개의 알코올 (al cohol ) , 아세톤 (acetone), 에테르 (ether ) , 벤젠 (benzene)ᅳ 클로로포름 (chloroform) , 에틸아세테이트 (ethyl acetate) , 메틸렌클로라이드 (methylene chlor ide) , 헥산 (hexane) , 시클로핵산 (cyc l ohexane) , 디에틸에테르 (di ethyl ether ) 및 석유에테르 (petroleum ether )로 이루어진 군 중에서 선택된 것일 수 있다. 바람직하게 물 또는 탄소수 1 내지 6개 의 알코올을 사용하여 추출할 수 있다. The Chinese quince extract may be extracted by a known natural product extraction method, preferably extracted with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, and subcritical or supercritical euse. The organic solvent having 1 to 6 carbon atoms may be 1 to 6 carbon atoms (al cohol), acetone (acetone), ether (ether), benzene (chloroform) chloroform, ethyl acetate (ethyl acetate) It may be selected from the group consisting of methylene chloride (methylene chloride), hexane (hexane), cyclonucleic acid (cyc l ohexane), diethyl ether and petroleum ether. Preferably it can be extracted using water or alcohol having 1 to 6 carbon atoms.
<124> <124>
<125> 본 발명의 모과나무를 유효성분으로 포함하는 약학적 조성물은 유효량으로 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있다. 상 기에서 "유효량"이란, 개체에 투여하였을 때, 골 성장을 나타내는 양을 말하며, 상 기 "개체 (subj ect ) "란 동물, 바람직하게는 포유동물, 특히 인간을 포함하는 동물일 수 있다. 상기 개체는 골 성장이 필요한 성장기 환자일 수 있다. A pharmaceutical composition comprising the Chinese quince tree as an active ingredient may be administered in various amounts, including oral, transdermal, subcutaneous, intravenous or intramuscular. As used herein, the term "effective amount" refers to an amount indicating bone growth when administered to an individual, and the term "subj ect" may be an animal, preferably a mammal, particularly an animal including a human. The subject may be a growth patient in need of bone growth.
<126> <126>
<127> 상기 본 발명의 모과나무 추출물 그 자체를 그대로 투여하거나 상술한 바와 같은 여러 제형으로 제조되어 투여될 수 있으며, 바람직하게는 원하는 효과 즉 성 장 효과가 도출될 때 까지 투여될 수 있다. 본 발명의 모과나무를 유효성분으로 포
함하는 약학적 조성물은 당업계에 공지된 방법에 따라 다양한 경로로 투여될 수 있 다. 즉, 경구 또는 비경구, 예컨대 구강, 근육내, 정맥내, 피내, 동맥내, 골수내, 경막내, 복강내, 비강내, 질내, 직장내, 설하 또는 피하 투여되거나, 위장관, 점막 또는 호흡기로 투여될 수 있다ᅳ 【유리한 효과】 The Chinese quince extract of the present invention may be administered as it is, or prepared and administered in various formulations as described above, and preferably, may be administered until a desired effect, that is, a growth effect, is derived. Chinese quince tree of the present invention as an active ingredient Including pharmaceutical compositions can be administered by a variety of routes according to methods known in the art. That is orally or parenterally, such as oral, intramuscular, intravenous, intradermal, intraarterial, intramedullary, intradural, intraperitoneal, intranasal, intravaginal, rectal, sublingual or subcutaneous, or into the gastrointestinal tract, mucosa or respiratory tract. Can be administered ᅳ [Effective Effect]
본 발명의 모과나무를 유효성분으로 포함하는 조성물은 성장판 및 장골 (long bone)의 성장 촉진 효과가 있어, 성장기의 유소아 및 청소년의 성장 및 골격 형성 을 촉진하는데 효과적이다. 뿐만 아니라 본 발명의 조성물 단독으로 또는 성장호르 몬 치료와 병행요법을 통해 키 성장 치료에 효과적이다. The composition comprising the Chinese quince tree as an active ingredient has an effect of promoting growth of growth plates and long bones, and is effective in promoting growth and skeletal formation of infants and adolescents during the growing season. As well as the composition of the present invention alone or in combination with growth hormone treatment is effective for the treatment of height growth.
【도면의 간단한 설명】 [Brief Description of Drawings]
도 1은 투여 군별로 10일간 랫트 (rat)의 몸무게 변화 추이를 나타낸 도식이 다. 1 is a diagram showing the change in weight of rats (rat) for 10 days for each administration group.
도 2는 투여 군별로 랫트 경골 (tibia)의 micro-CT촬영 결과를 나타낸다. 도 3은 투여 군별로 랫트 경골의 X-ray촬영 결과를 나타낸다. Figure 2 shows the results of micro-CT imaging of rat tibia (tibia) for each administration group. Figure 3 shows the X-ray image of the rat tibia for each administration group.
도 4는 투여 군별로 랫트 총 경골 길이 (total tibia length)를 나타낸 것이 다. Figure 4 shows the total tibia length of the rat for each administration group (total tibia length).
도 5는 각 투여 군별로 랫트의 성장판에서 증식부 (proliferative zone) 및 비대부 (hypertrophic zone)의 위치 및 상대적 길이를 나타낸 것이다 (control: saline 투여군, GH: 성장호르몬 투여군, 목과: 목과 추출물 투여군). Figure 5 shows the location and relative length of the proliferative zone and hypertrophic zone in the growth plate of the rat for each administration group (control: saline administration group, GH: growth hormone administration group, neck and neck: neck and extract administration group) .
도 6은 각 투여군의 성장판 (growth plate) 영역 중 증식부 (prol i ferat ive zone)의 길이를 나타낸 도식이다 (control: saline 투여군, 성장: 성장호르몬 투여 군, 목과: 목과 추출물 투여군). 6 is a diagram showing the length of the proliferation zone (prol i ferative zone) in the growth plate (growth plate) area of each administration group (control: saline administration group, growth: growth hormone administration group, neck: neck and extract administration group).
도 7은 각 투여군의 성장판 (growth plate) 영역 중 비대부 (hypertrophic zone)의 길이를 나타낸 도식이다 (control: saline 투여군, 성장: 성장호르몬 투여 군, 목과: 목과 추출물 투여군). Figure 7 is a diagram showing the length of the hypertrophic zone of the growth plate (growth plate) area of each administration group (control: saline administration group, growth: growth hormone administration group, neck and neck: neck and extract administration group).
도 8은 각 투여군의 연골조직을 BrdU staining한 결과를 이미지로 나타낸 다. Figure 8 shows the results of BrdU staining the cartilage tissue of each administration group as an image.
도 9는 각 투여군의 연골조직에서 BrdU positive cell의 비율을 나타낸다. 도 10은 각 투여군에서 혈장속의 오스테오칼신 (osteocalcin)농도를 측정한 결과를 나타낸다.
<141> Figure 9 shows the ratio of BrdU positive cells in the cartilage tissue of each administration group. Figure 10 shows the results of measuring the concentration of osteocalcin (osteocalcin) in the plasma in each administration group. <141>
【발명의 실시를 위한 형태】 [Form for implementation of invention]
<142> 이하 본 발명을 상세히 설명한다ᅳ Hereinafter, the present invention will be described in detail.
<143> 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실 시예에 한정되는 것은 아니다. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
<144> <144>
<145> <실시예 1> <145> <Example 1>
<146> 모과나무 (목과) 추출물의 제조 <146> Preparation of Chinese Quince Extract
<147> 목과는 동양산업제약사 (층북 보은군 보은읍 풍취리 18번지)에서 구입하였다. <147> The tree was purchased from Dongyang Pharmaceutical Co., Ltd.
50L 추출기 (가압추출기, 고려산업)를 이용하여 20~40mesh의 크기로 분쇄한 목과 600g (건조중량), 물 10L를 넣고 lOCTC에서 2시간씩 2회 열수 추출한다. 상기 열수 추출액을 실온에서 방치하여, 실온으로 식힌 후 여과한다. 여과한 추출액을 20L evaporator (Rotory Evaporator , HEID0LPH)로 고형분이 15중량 % 될 때까지 농축 (연 조액스 전 단계로 고형분 33.27g)하여 농축액을 제조한다. 상기 농축액에 고형분과 동일한 중량의 결정셀를로오스를 흔합한 후, 건조기로 2일 동안 건조 ( i(xrc 열풍건 조)하여 수분이 모두 증발하고 남은 66.79g의 목과 추출물 분말을 수득했다. Using 50L extractor (Pressure extractor, Korea Industrial Co., Ltd.), add crushed neck, 600g (dry weight), and 10L of water into 20 ~ 40mesh, and extract hot water twice at lOCTC for 2 hours. The hot water extract is left at room temperature, cooled to room temperature and filtered. The filtered extract was concentrated with 20 L evaporator (Rotory Evaporator, HEID0LPH) until the solid content became 15% by weight (solid content 33.27 g of the solid solution before the pre-mixed solution) to prepare a concentrate. After mixing the crystalline cells of the same weight as the solids in the concentrate, and dried for 2 days (i (xrc hot air drying)) in a dryer to obtain the remaining 66.79g of the neck and extract powder after evaporation of all moisture.
<148> <148>
<149> <실험예 1> <149> <Experimental Example 1>
<150> 동물모델을 이용하 모과나무 추출물의 성장 촉진 효과 조사 <150> Investigation of Growth Promotion Effect of Chinese Quince Extract Using Animal Model
<151> <151>
<152> <1-1>모과나무 (목과) 추출물의 투여 <1-1> Administration of Extract of the Chinese Quince (Thursaceae)
<153> 3주령의 Male Spr ague-Daw ley rat를 구입하여 사흘 동안 안정화시켰다. 사육 환경은 24士 2°C , 명암주기는 12시간 간격을 유지하고 사료는 항생제가 첨가되지 않 은 일반 고형사료를 사용하였다. Control 군에는 sal ine을 주입하며, 목과 추출물 을 경구투여로써 일일 1회 경구 투여하였다 (상기 <실시예 1>에서 제조한 목과 추출 물 분말을 물에 녹여 투약함) . Posi t ive 군에는 유트로핀주 (LG생명과학)를 20/ g/ kg의 용량으로써 일일 1회 피하 주사하였다. 본 발명의 목과 추출물 투여 방법은, Rat에게 posi t ive 군을 제외한 모든 군에서 oral cavi ty에 투여하며 모든 동물은 dai ly 1회 투.여한다. 각 군의 구성은 아래와 같다. Three-week-old Male Sprague-Daw ley rats were purchased and stabilized for three days. The breeding environment was maintained at 24 ° C 2 ° C, and the light and dark cycles were kept for 12 hours, and the feed was used as a general solid feed without antibiotics. The control group was infused with sal ine, and the oral and extracts were orally administered once daily by oral administration (the neck and extract powder prepared in Example 1 was dissolved in water and administered). In the Positiv group, Eutropin (LG Life Sciences) was injected subcutaneously once daily at a dose of 20 / g / kg. In the neck and extract administration method of the present invention, rats are administered to oral cavi ty in all groups except the posi ive group, and all animals are administered once daily. The composition of each group is as follows.
<154> - Control 투여군 ·' Normal sal ine lml <154>-Control administration group ' Normal sal ine lml
<155> 一 Posi t ive Control : growth hormone , 20 ig/ kg <155> 一 Posi t ive Control : growth hormone, 20 ig / kg
<156> - 목과 투여군 200mg/ kg
<157> Neck and administration group 200 mg / kg <157>
<158> 10일간의 사료의 섭취와 목과 추출물의 투여가 끝난 후에 부검하여 아래 내 용을 확인한다 . <158> After 10 days of ingestion of feed and neck and extracts, an autopsy confirms the following.
<159> <159>
<160> <1-2>실험동물의 체중 변화 <160> <1-2> Weight Change of Experimental Animal
<161> 상기 실험예 <1-1>의 각 그룹의 식이 투여 전 체증과 10일간 식이 투여 후 체중을 측정하였다. 측정은 주 2회 실시되었다. 측정된 값은 통계처리하여 평균값 과 표준편차를 계산하였다. The weight of each group of Experimental Example <1-1> before dietary administration and after dietary administration for 10 days was measured. The measurement was performed twice a week. The measured values were statistically calculated to calculate the mean and standard deviation.
<162> <162>
<163> [도 1]에서 보는바와 같이, 10일간 관찰한 결과 Control군, 실험군, 성장호 르몬 투여군 모두에서 몸무게의 차이가 거의 없는 것으로 나타났다. 이는 마우스의 ' 몸무게가 목과 투약의 효과와 상관관계가 크게 없다는 것을 나타낸다. As shown in FIG. 1, 10 days of observation showed that there was almost no difference in weight in the control group, the experimental group, and the growth hormone administration group. This indicates that the mouse 'weight is not significantly correlated with the effect of neck and dosing.
<164> <164>
<165> <165>
<166> *<1-3> 뼈의 이상 증식 및 골다공증 (Osteoporosi s) 독성 평가 <166> * <1-3> Assessment of Osteoporosi s Toxicity in Bone Abnormal Proliferation and Osteoporosis
<167> 상기 실험예 <1-1>에서 10일 간의 투여가 완료된 후 본 발명에 따른 모과나 무 추출물을 섭취시킨 실험군 및 대조군에서, 뼈의 과잉성장 또는 골다공증 In the experimental group and the control group ingested the Chinese quince or radish extract according to the present invention after the administration for 10 days in the Experimental Example <1-1>, overgrowth of bone or osteoporosis
(osteoporosi s) 이상 유무를 micro-CT 방법으로 평가하였다. The presence or absence of (osteoporosi s) was evaluated by the micro-CT method.
<168> 왼쪽 경골의 골밀도와 관련된 소주골 (trabecular bone)의 용적 및 두께를 micro-CT 검사로 확인하였다. 랫트를 치사시켜 왼쪽 경골을 추출한 상태에서 micro-CT를 이용하여 소주골 용적 및 소주골 두께를 측정하였다. Mi cro— CT시스템은 SKYSCAN 1172 mi cro-CT 기기를 사용하였으며 X-ray source는 50kV, 200mA로 하였 다. 소스와 디텍터가 고정되어 있고 그 사이에 물체가 회전함으로 투영데이테를 얻 는다. 영상은 0.8um - 25um 픽셀의 크기를 가진다. Micro-CT로 왼쪽 경골부 목부분 에 전체적 F0V( f ield of view) 스캔하고 제한된 영역 (region of interest (R0I )의 부분 F0V 스캔하여 정확한 rat ios 를 파악한다. (Chunet al 2004) . 이 F0V영역을 재구성하여 골소주 (trabeculae)의 비율과 두께를 구한다. 2D 영상의 왼쪽 대퇴골의 직사각형의 내부에 있는 소주골 (trabecula)의 용적비율 (BV/TV, %)과 골소주 두께 (Tb .Th, mm)을 계산하기 위해 fuzzy di stance transform (FDT) 알고리즘을 적용하 였다 ( In Kon Chunl . , et al . , In vivo trabecular thickness measurement in cancel lous bones : longi tudinal rat imaging studies . Phys iol . Meas . 27(2006)695-702)
<169> The volume and thickness of the trabecular bone associated with the bone density of the left tibia were confirmed by micro-CT examination. In the state where the left tibia was extracted by lethal rats, the volume and the thickness of the trabecular bone were measured using micro-CT. Mi cro— CT system uses SKYSCAN 1172 mi cro-CT device and X-ray source is 50kV, 200mA. The source and detector are fixed and the object rotates between them to obtain projection data. The image has a size of 0.8um-25um pixels. Use a micro-CT to scan the entire F0V (Field of view) of the left tibia neck and a partial F0V scan of the region of interest (R0I) to determine the correct rat ios (Chunet al 2004). The ratio and thickness of trabeculae are calculated by reconstructing the volume ratio of trabecula (BV / TV,%) and bone thickness (Tb.Th, mm) inside the rectangle of the left femur in the 2D image. The fuzzy di stance transform (FDT) algorithm was applied (In Kon Chunl., Et al., In vivo trabecular thickness measurement in cancel lous bones: longi tudinal rat imaging studies. Phys iol. Meas. 27 (2006) ) 695-702) <169>
<170> micro— CT를 통해 살펴본 골 부피의 백분율 (percentage bone volume), 골소주 간극 (trabecular separation), 골소주 두께 (trabecular thickness) 등은 주로 osteoporosis 유무 및 뼈 이상을 평가하는 지표로 사용된다. [도 2] 및 표 1에서 보는 바와 같이, 각 군 간의 차이가 거의 없는 것으로 보아, 실험 기간 동안 이 생 약들이 뼈의 이상증식 또는 골다공증 (Osteoporosis) 독성 등에 영향이 없음을 알 수 있다. Micro—Percentage bone volume, trabecular separation, and trabecular thickness as viewed through CT are mainly used as indicators for osteoporosis and bone abnormality. As shown in FIG. 2 and Table 1, there is almost no difference between the groups, and it can be seen that these drugs do not affect the abnormal growth of bone or osteoporosis toxicity during the experimental period.
<171> <171>
<172> 【표 1】 <172> [Table 1]
<173> <173>
<174> <174>
<i75> <l-4>실험동물의 경골 (tibia) 길이 변화 측정 <i75> <l-4> Measurement of tibia length changes in experimental animals
<176> 상기 실험예 <1-1〉에서 10일 간의 투여가 완료된 후, 본 발명에 따른 모과나 무 추출물을 섭취시킨 실험군 및 대조군의 좌우 경골 (정강이뼈)를 적출하여 뼈 조 직에 부착되어 있는 근육, 지방, 인대 등을 전부 제거하고 70% 알코을에 보관하고 X-ray 촬영기기 (0M-F0RTE -10121ᅳ DK 메디칼시스템)를 이용하였다. X-ray source는 55kV, 320mA로 하였다. 경골의 X-ray 촬영을 통해 경골 길이 (tibia length)를 측정 하였다. After the administration for 10 days in the Experimental Example <1-1> is completed, the left and right tibia (shalp bone) of the experimental group and the control group ingested the Chinese quince or radish extract according to the present invention is attached to the bone tissue All muscles, fats, ligaments, etc. were removed and stored in 70% alcohol and X-ray equipment (0M-F0RTE -10121 ᅳ DK Medical System) was used. X-ray source was 55kV, 320mA. Tibia length was measured by X-ray imaging of the tibia.
<177> <177>
<178> [도 3] 및 [도 4]에서 보는 바와 같이 Control 군에 비해 성장호르몬을 투 As shown in FIG. 3 and FIG. 4, growth hormones were increased compared to the control group.
여한 군의 total tibia length가 증가하였으며, 목과를 투여한 군에서도 Control 군에 비하여 total tibia length가 증가하는 효과를 보였다. The total tibia length was increased in the other groups, and the total tibia length was also increased in the group treated with the neck compared to the control group.
<179> <179>
<180> <1-5>실험동물의 성장판 연골조직 변화 측정 <180> <1-5> Measurement of Growth Plate Cartilage Change in Experimental Animals
<i8i> 성장판 영역 (Growth plate zone)의 길이는 부검 후 연골조직을 고정하여 H&E staining 기법으로 염색 후 현미경을 이용한다. 각 zone의 길이를 한 sample당 5번 씩 측정하여 평균을 낸 값을 대표값으로 사용하여 유의성을 평가한다.
<182> <i8i> The length of the growth plate zone is fixed by cartilage tissue after autopsy and stained by H & E staining technique, followed by microscopy. Measure the length of each zone 5 times per sample and use the averaged value as a representative value to evaluate the significance. <182>
<i83> [도 5] 내지 [도 기에서 보는 바와 같이, Control 군에 비해 성장호르몬을 투여한 군의 proliferative zone 및 hypertrophic zone의 길이가 증가하였으며, 목 과 투여군의 경우도 proliferative zone 및 hypertrophic zone의 길이가 Control 군에 비해 유의성 있게 증가하였다. As shown in FIG. 5 to FIG. 5, the proliferative and hypertrophic zones of the growth hormone-administered group were increased compared to the control group, and the proliferative and hypertrophic zones of the neck and administration groups were also increased. The length increased significantly compared to the control group.
<184> <184>
<185> <1-6>연골세포 (chondrocyte) 증식 효과 <185> <1-6> Chondrocyte proliferation effect
<186> chondrocyte prol i ferat ion의 정도를 측정하기 위하여, Rat 경골 (tibia)의 연골조직을 이용하였고 이 부위의 성장판에 있는 S phase상태의 proliferative cell에 brdU staining 방법을 적용하였다. Sigma사의 5-Bromo-2-deoxyur idine (제 품번호: B9285)를 ammonium hydroxide(NH40H)0.1M에 30mg/kg의 용량으로 녹여 실험종 료 1시간 전에 복강 투여하였으며, 부검 후 연골조직을 고정하여 paraffin embedded tissue를 만들었고 BrdU staining kit (Invitrogen, 93-3943)의 방법대로 staining을 진행하였다. BrdU positive ceH은 cell counter를 이용하여 counting 하였다. In order to measure the degree of chondrocyte proliferation, rat tibial cartilage tissue was used and brdU staining was applied to S phase proliferative cells in the growth plate of this region. Sigma 5-Bromo-2-deoxyur idine (Product No .: B9285) was dissolved in ammonium hydroxide (NH 4 0H) 0.1M at a dose of 30 mg / kg and intraperitoneally administered 1 hour prior to the end of the experiment. Paraffin embedded tissues were fixed and stained by BrdU staining kit (Invitrogen, 93-3943). BrdU positive ceH was counted using a cell counter.
<187> <187>
<188> 그 결과 [도 8] 및 [도 9]에서 보는 바와 같이, Control군에 비해 성장호르 몬군과 목과 투여군 모두 비슷한 수준으로 BrdU positive cell 비율이 증가하였다. 이는 목과 투여군이 연골세포 증식효과가 있음을 나타낸다. As a result, as shown in FIGS. 8 and 9, the growth rate of BrdU positive cells was increased to a similar level in both the growth hormone group and the neck and administration groups compared to the control group. This indicates that the neck and the administration group have a chondrocyte proliferation effect.
<189> <189>
<190> <1-7>골아세포 활성인자 혈장 오스테오칼신 (osteocalcin) 측정 <190> <1-7> Osteoblast Activator Plasma Osteocalcin Measurement
<i9i> rat의 혈액을 투약이 끝난 후 심장에서 채취하여 웅고시킨후 serum을 분리하 여 샘플을 만들었고, Rat Ostecalcin/Bone Gla Protein. OT/BGP EL ISA Kit (Cusabio, 제품번호: CSB— E05129r)를 사용하여 serum내 total osteocalcin level을 측정하였다. <i9i> Rat blood was collected from the heart after administration and uncoated, and serum was isolated to make a sample. Rat Ostecalcin / Bone Gla Protein. Total osteocalcin levels in serum were measured using the OT / BGP EL ISA Kit (Cusabio, product number: CSB—E05129r).
<192> <192>
<193> 그 결과 [도 1이에서 보는 바와 같이, 성장호르몬 투여군 및 목과 추출물 투 여군 모두에서 혈장 내 오스테오칼신 레벨이 control 군에 비하여 유의적으로 증가 하는 것을 확인하였다. 특히, 목과 투여군에서 성장호르몬 투여군과 비교하여 오스 테오칼신 레벨이 조금 더 높은 결과가 나타났다. 오스테오칼신은 골아세포에서 형 성된 후에 골기질속에 침착되며 새로이 형성되는 오스테오칼신의 일부는 혈액 내로 방출되므로 혈중 농도를 측정하면 골형성 정도를 알 수 있어, 혈장내 오스테오칼신
농도는 골아세포의 활성을 반영하는 것으로 보고 있다. 본 발명의 목과 추출물이 혈장내 오스테오칼신의 농도를 유의성있게 증가시는 것으로 보아, 골형성 및 골아 세포 활성이 증가되는 것으로 보여진다. As a result, as shown in FIG. 1, it was confirmed that the plasma osteocalcin level was significantly increased in both the growth hormone administration group and the neck and extract administration group compared with the control group. In particular, the results of slightly higher levels of osteocalcin were found in the neck and administration groups compared to the growth hormone administration group. Osteocalcin is formed in osteoblasts and then deposited in the bone matrix, and some of the newly formed osteocalcin is released into the blood. Therefore, the level of bone formation can be determined by measuring blood levels. Concentrations are believed to reflect the activity of osteoblasts. It has been shown that the neck and extract of the present invention significantly increase the concentration of osteocalcin in plasma, resulting in increased bone formation and osteoblast activity.
<194> <194>
【산업상 이용가능성】 Industrial Applicability
<195> 이상 살펴본 바와 같이, 본 발명은 모과나무의 성장 촉진 효과에 관한 것으 로, 더욱 상세하게는 모과나무를 유효성분으로 포함하는 성장 촉진용 약학적 조성 물, 식품 조성물 및 동물 사료용 조성물에 관한 것이다. As described above, the present invention relates to a growth promoting effect of a Chinese quince, and more particularly to a pharmaceutical composition for promoting growth, a food composition and a composition for animal feed comprising the Chinese quince as an active ingredient. will be.
<196> 본 발명의 모과나무를 유효성분으로 포함하는 조성물은 성장판 및 장골의 성 장 촉진 효과가 있어, 성장기의 유소아 및 청소년의 성장 및 골격 형성을 촉진하는 데 효과적일뿐만 아니라 본 발명의 조성물 단독으로 또는 성장호르몬 치료와 병행 요법을 통해 키 성장 치료에 효과적이므로 산업상 이용가능성이 크다 .
The composition comprising the Chinese quince of the present invention as an active ingredient has an effect of promoting growth of growth plates and iliac bone, and is effective in promoting growth and skeletal formation of infants and adolescents during the growing season, as well as the composition of the present invention. It is highly industrially available because it is effective for the treatment of height growth, either through or in combination with growth hormone therapy.
Claims
【청구항 1】 【Claim 1】
모과나무를 유효성분으로 포함하는 성장 촉진용 약학적 조성물. A pharmaceutical composition for growth promotion containing quince as an active ingredient.
【청구항 2】 【Claim 2】
모과나무를 유효성분으로 포함하는 성장 촉진용 식품 조성물. A food composition for growth promotion containing quince as an active ingredient.
【청구항 3】 【Claim 3】
모과나무를 유효성분으로 포함하는 성장 촉진용 동물 사료용 조성물. A composition for animal feed for growth promotion containing quince as an active ingredient.
【청구항 4】 【Claim 4】
게 1항 내지 게 3항 중 어느 한 항에 있어서, 상기 모과나무는 모과나무의 열 매, 잎, 꽃, 줄기 및 뿌리로 이루어진 군에서 선택된 하나 이상의 것임을 특징으로 하는 성장 촉진용 조성물. The composition for promoting growth according to any one of paragraphs 1 to 3, wherein the quince tree is one or more selected from the group consisting of fruits, leaves, flowers, stems, and roots of the quince tree.
【청구항 5】 【Claim 5】
거 U항 내지 제 4항 중 어느 한 항에 있어서, 상기 모과나무는 모과나무 추출 물인 것을 특징으로 하는 성장 촉진용 조성물. The composition for growth promotion according to any one of paragraphs U to 4, wherein the quince tree is a quince tree extract.
【청구항 6】 【Claim 6】
제 5항에 있어서, 상기 모과나무 추출물은 물 탄소수 1 내지 6개의 알코을, 아세톤, 에테르, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 핵산, 시클로핵 산, 석유에테르 (petroleum ether ) , 디에틸에테르, 벤젠 및 아임계 또는 초임계 유 체로 이루어진 군에서 선택된 하나 이상의 용매에 의한 추출물인 것을 특징으로 하 는 성장 촉진용 조성물. According to claim 5, the quince tree extract is water, alcohol with 1 to 6 carbon atoms, acetone, ether, chloroform, ethyl acetate, methylene chloride, nucleic acid, cyclonucleic acid, petroleum ether, diethyl ether, benzene, and A composition for promoting growth, characterized in that it is an extract using at least one solvent selected from the group consisting of subcritical or supercritical fluids.
【청구항 7】 【Claim 7】
제 1항 내지 제 6항 중 어느 한 항에 있어서, 상기 성장은 골 성장인 것을 특 징으로 하는 성장 촉진용 조성물. The composition for promoting growth according to any one of claims 1 to 6, wherein the growth is bone growth.
【청구항 8】 【Claim 8】
성장 촉진제 제조를 위한 모과나무의 용도.
Use of quince tree for manufacturing growth promoters.
【청구항 9] [Claim 9]
성장 촉진용 식품 조성물 제조를 위한 모과나무의 용도. Use of quince tree for manufacturing food compositions for growth promotion.
【청구항 10】 【Claim 10】
성장 촉진용 동물 사료 제조를 위한 모과나무의 용도. Use of quince tree to manufacture growth-promoting animal feed.
【청구항 11】 【Claim 11】
제 8항 내지 제 10항 중 어느 한 항에 있어세 상기 모과나무는 모과나무의 열 매, 잎, 꽃, 줄기 및 뿌리로 이루어진 군에서 선택된 하나 이상의 것임을 특징으로 하는 모과나무의 용도. The use of the quince tree according to any one of claims 8 to 10, wherein the quince tree is one or more selected from the group consisting of fruits, leaves, flowers, stems and roots of the quince tree.
【청구항 12] [Claim 12]
게 8항 내지 제 11항 증 어느 한 항에 있어서, 상기 모과나무는 모과 추출물인 것을 특징으로 하는 모과나무의 용도. The use of the quince tree according to any one of paragraphs 8 to 11, wherein the quince tree is a quince extract.
【청구항 13] [Claim 13]
제 12항에 있어서, 상기 모과나무 추출물은 물, 탄소수 1 내지 6개의 알코을, 아세톤, 에테르, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 핵산, 시클로핵 산, 석유에테르 (pet rol eum ether ) , 디에틸에테르, 벤젠 및 아임계 또는 초임계 유 체로 이루어진 군에서 선택된 하나 이상의 용매에 의한 추출물인 것을 특징으로 하 는 모과나무의 용도. The method of claim 12, wherein the quince tree extract is water, alcohol having 1 to 6 carbon atoms, acetone, ether, chloroform, ethyl acetate, methylene chloride, nucleic acid, cyclonucleic acid, petroleum ether (petrol eum ether), and diethyl ether. , Use of quince tree, characterized in that it is an extract by one or more solvents selected from the group consisting of benzene and subcritical or supercritical fluid.
【청구항 14] [Claim 14]
제 8항 내지 제 10항 중 어느 한 항에 있어서, 상기 성장은 골 성장인 것을 특 징으로 하는 모과나무의 용도. 11. Use of quince according to any one of claims 8 to 10, wherein the growth is bone growth.
【청구항 15】 【Claim 15】
성장을 필요로 하는 개체에 유효량의 모과나무를 투여하는 것을 특징으로 하 는 성장 촉진 방법. A growth promotion method comprising administering an effective amount of quince to an individual in need of growth.
【청구항 16]
제 15항에 있어서, 상기 모과나무는 모과나무의 열매, 잎, 꽃, 줄기 및 뿌리 로 이루어진 군에서 선택된 하나 이상의 것임을 특징으로 하는 성장 촉진 방법. [Claim 16] The method of claim 15, wherein the quince tree is one or more selected from the group consisting of fruits, leaves, flowers, stems and roots of quince trees.
【청구항 17] [Claim 17]
제 15항에 있어서, 상기 모과나무는 모과 추출물인 것을 특징으로 하는 성장 촉진 방법 . The method of claim 15, wherein the quince tree is a quince extract.
【청구항 18] [Claim 18]
제 17항에 있어서, 상기 모과나무 추출물은 물, 탄소수 1 내지 6개의 알코올ᅵ 아세톤, 에테르, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 핵산, 시클로헥 산, 석유에테르 (petrol eum ether ) , 디에틸에테르, 벤젠 및 아임계 또는 초임계 유 체로 이루어진 군에서 선택된 하나 이상의 용매에 의한 추출물인 것을 특징으로 하 는 성장 촉진 방법. The method of claim 17, wherein the quince tree extract contains water, an alcohol having 1 to 6 carbon atoms , acetone, ether, chloroform, ethyl acetate, methylene chloride, nucleic acid, cyclohexane, petroleum ether, diethyl ether, A method for promoting growth, characterized in that the extraction is performed using at least one solvent selected from the group consisting of benzene and subcritical or supercritical fluids.
【청구항 19] [Claim 19]
제 16항 내지 제 18항 중 어느 한 항에 있어서, 상기 성장은 골 성장인 것을 특징으로 하는 성장 촉진 방법 .
19. The method of any one of claims 16 to 18, wherein the growth is bone growth.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140036559A KR20150112419A (en) | 2014-03-28 | 2014-03-28 | Composition for promoting bone growth comprising quince tree |
KR10-2014-0036559 | 2014-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015147559A1 true WO2015147559A1 (en) | 2015-10-01 |
Family
ID=54195986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/002949 WO2015147559A1 (en) | 2014-03-28 | 2015-03-26 | Composition for promoting growth comprising chaenomeles sinesis as active ingredient |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20150112419A (en) |
WO (1) | WO2015147559A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100673266B1 (en) * | 2006-04-21 | 2007-01-24 | 박승만 | A growth-promoting composition |
KR20110038631A (en) * | 2008-06-24 | 2011-04-14 | 주식회사 바이로메드 | Crude drug composition for cartilage regeneration, pain suppression, and edema suppression |
KR101252630B1 (en) * | 2012-07-06 | 2013-04-09 | 우상하 | Useful composition for growth and development of children and youths |
-
2014
- 2014-03-28 KR KR1020140036559A patent/KR20150112419A/en not_active Application Discontinuation
-
2015
- 2015-03-26 WO PCT/KR2015/002949 patent/WO2015147559A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100673266B1 (en) * | 2006-04-21 | 2007-01-24 | 박승만 | A growth-promoting composition |
KR20110038631A (en) * | 2008-06-24 | 2011-04-14 | 주식회사 바이로메드 | Crude drug composition for cartilage regeneration, pain suppression, and edema suppression |
KR101252630B1 (en) * | 2012-07-06 | 2013-04-09 | 우상하 | Useful composition for growth and development of children and youths |
Non-Patent Citations (2)
Title |
---|
TAE-YUNG CHUNG ET AL.: "Nonvolatile Flavor Components in Chinese Quince Fruits, Chaenomeles sinensis koehne", KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 20, no. 3, 1988, pages 293 - 302, XP055227233 * |
WANG JINJIN ET AL.: "Effects of dietary calcium and phosphorus levels on bone growth in broilers from 1 to 3 weeks of age", CHINESE JOURNAL OF ANIMAL NUTRITION, vol. 22, no. 4, 2010, pages 1088, XP055227238 * |
Also Published As
Publication number | Publication date |
---|---|
KR20150112419A (en) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
JP6112895B2 (en) | Composition for prevention, amelioration or treatment of metabolic syndrome | |
KR20060022668A (en) | Compositions and foods and drinks contiaing higher fatty acid derivative | |
JP2010265251A (en) | Bloodstream-promoting/improving agent | |
JP4812222B2 (en) | Mineral absorption promoter | |
JP2018070570A (en) | Lindera plant extract | |
JP6944221B2 (en) | Composition for prevention, amelioration or treatment of bone loss disease containing CHP (cyclo-hispro) | |
KR20200140749A (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata | |
KR102081984B1 (en) | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis | |
KR101642176B1 (en) | Composition for enhancing growth and reinforcing immunity | |
EP1583547A1 (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
WO2015190682A1 (en) | Composition for growth promotion, containing coumaric acid as active ingredient | |
JP2008531552A (en) | Mixed herbal extract of ripening yellow and five peels and composition for prevention and treatment of osteoporosis containing the same as an active ingredient | |
JP6094985B2 (en) | A novel application of hot water extract of intermediate layer with removal of rough stems in bamboo to promote bone length growth | |
WO2015147559A1 (en) | Composition for promoting growth comprising chaenomeles sinesis as active ingredient | |
JP5986285B1 (en) | Calcium absorption promoter | |
KR102380295B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of oat | |
JP2009096719A (en) | Osteoclast differentiation inhibitor | |
JP2021525222A (en) | Compositions for the prevention or treatment of osteoporosis | |
WO2014185824A1 (en) | Additive made from vegetable material and method for producing same | |
JP5008813B2 (en) | Anti-Skin Cancer Agent Containing Cubileta Extract | |
JP2005239686A (en) | Body fat combustion promotion composition and food or medicine containing the same | |
KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
US20180021268A1 (en) | Weight loss/reduction of visceral fat compound and method of extraction and preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15769423 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15769423 Country of ref document: EP Kind code of ref document: A1 |